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I. Liposomes
of T3 are mediated by thyroid 
hormone nuclear receptors, 
the TRs, which act as tran-
scription factors [5,6]. TRs 
are members of the steroid/
thyroid receptor superfamily 
of nuclear hormone receptors, 
which includes the two reti-
noid acid receptors (RAR and 
RXR), the vitamin D receptor 
(VDR), the peroxisome prolif-
erators-activated receptor 
(PPAR), the constitutive an-
drostane receptor (CAR), and 
some orphan receptors [7]. 
Two different TR subtypes, TRα 
and TRβ, have been identified 
which are the products of dis-
tinct genes [8]. The TRα1 and 
the TRβ1 isoforms bind thy-
roid hormone with near-equal 
affinity, and are ubiquitously 
expressed, although TRα1 pre-
dominates in the heart (50–
70% of TRs) while TRβ1 pre-
dominates in the liver (80% 
of TRs) [7]. Data collected 
from various TR knockout mice 
suggest that TRα1 mediates 
the effects of thyroid hor-
mones of heart rate, whereas 
TRβ1 is important in mediat-
ing the cholesterol-lowering 
and TSH suppressant effects of 
T3 [8]. Paradoxically, al-
1. Introduction
Hepatocellular carcinoma 
(HCC) is one of the most com-
mon malignant tumors which 
can result from several liv-
er diseases such as hepatitis 
B and C infections, metabol-
ic liver diseases and non-al-
coholic fatty liver diseases 
[1]. Malignant transforma-
tions of hepatocytes induced 
by viral factors and sever-
al mediators in the chroni-
cally inflamed area lead to 
hepatocarcinogenesis. HCC is 
the sixth most common cancer 
(in male) and the third lead-
ing cause of cancer associat-
ed deaths in the world [2,3].
 
1.1. Triiodothyronine (T3) 
and Thyroid hormone receptors 
(TRs)
3,5,3’-triiodo-L-thyronine 
(T3) (Figure 1), a thyroid 
hormone (TH) normally syn-
thesized and secreted by 
the thyroid gland, influenc-
es a variety of physiologi-
cal processes, including cell 
growth and metabolism in mam-
mals, metamorphosis in am-
phibians, and development of 
the vertebrate nervous sys-
tem [4]. Most of the effects 
1.Liposomes for triiodothyronine delivery to hepatoma 
cells: development, characterization and in vitro 
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Figure 1 3,5,3’-triiodo-L-thyronine (T3) structure
though the thyroid hormones 
stimulate liver prolifera-
tion and enhance liver regen-
eration, they also induce a 
rapid regression of carcino-
gen-induced hepatic nodules, 
and reduce the incidence of 
hepatocarcinoma and lung me-
tastasis [9,10]. TRβ-specif-
ic agonist GC-1 also reduces 
the number of preneoplas-
tic foci generated in exper-
imental models of liver car-
cinogenesis in rodents but 
T3 exhibits a stronger ef-
fect than GC-1, suggesting 
that TRα could also contrib-
ute to the antineoplastic ef-
fects of the hormone [11]. 
The biochemical phenotype of 
the preneoplastic hepatocytes 
closely resembles that of im-
mature hepatocytes since they 
lack hepatocyte differentia-
tion markers while express-
ing genes normally present 
during the fetal or neonatal 
period. Treatment with T3 or 
GC-1 causes the loss of sev-
eral markers associated with 
preneoplasia showing that TRs 
ligands promote remodeling of 
the preneoplastic lesions. 
Therefore, it has been postu-
lated that the mitogenic ac-
tivity mediated by activated 
TRs is associated with or fol-
lowed by a process of differen-
tiation [11]. In contrast to 
the mitogenic effect of THs in 
the liver, in hepatocarcinoma 
cells transfected with TR, T3 
down-regulates expression of 
pituitary tumor-transforming 
1 (PTTG1), a critical mitotic 
checkpoint protein [12]. Fur-
thermore, expression of TRβ1 
in hepatocarcinoma cells re-
tards tumor growth, causes 
partial mesenchymal to epi-
thelial cell transition and 
has a strong inhibitory ef-
fect on invasion, extravasa-
tion and metastasis formation 
in nude mice [13,14]. In cul-
tured hepatocarcinoma cells, 
and also in breast cancer 
cells, TRβ1 abolishes anchor-
age-independent growth and 
migration, disrupts the mito-
genic action of growth fac-
tors suppressing activation 
of signaling pathways that 
are crucial for cell prolif-
eration and invasiveness, and 
represses expression of genes 
that are relevant for meta-
static progression [14]. No-
tably, the antitumoral prop-
erty of T3 appears to be 
HO O
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Figure 2 Schematics of the Enhanced Permeability and Retention (EPR) effect or 
“passive” targeting. Passive tissue targeting is achieved by extravasation of 
nanoparticles through increased permeability of the tumor vasculature and inef-
fective lymphatic drainage (EPR effect). (1) Drug-loaded nanocarrier; it cannot 
extravasate through normal endothelium and only small molecules of free drug 
(4) can traverse normal endothelium to a certain extent in both directions; (2) 
gaps between endothelial cells appear in pathological areas (3) (such as tum-
ors, infarcts, and inflammations), through which nanoparticles can extravasate 
and accumulate in such areas creating high local drug concentrations. Adapt-
ed from Ref. [23]
specific and not shared by 
other liver mitogens, such as 
ciprofibrate, a member of the 
class of peroxisome prolifer-
ators [10]. All these findings 
suggest that thyroid hormone 
receptors constitute a novel 
therapeutic target in cancer. 
However, T3 administration is 
associated with serious side 
effects, particularly cardiac 
dysfunction, i.e. tachycar-
dia, arrhythmias, and precip-
itation of ischemic episodes 
or heart failure [15].
1.2. Nanosized vehicles for 
drug delivery in cancer
The ideal nanoscale drug de-
livery system should ensure 
that the conjugated or bound 
drug–carrier complex arrives 
and acts preferentially at 
the selected target. Target-
ing of the drug–nanocarrier 
complex can be active, where-
by the complex incorporates a 
ligand specific for the recep-
tor or epitope of the target 
tissue. In passive targeting, 
complexes diffuse and accumu-
late at sites with excessive-
ly leaky microvasculature, 
such as tumours and inflamed 
tissues, with normal endothe-
lium being much less permea-
ble. Subsequent extravasation 
of complexes takes place ei-
ther via transcytosis, where-
by macromolecules are inter-
nalized from the blood at 
points of invagination of the 
cell membrane, or paracellu-
larly, via diffusion through 
the tight junctions of en-
dothelial cells. Particularly 
in cancers, an imbalance in 
factors that regulate angio-
genesis, such as overexpres-
sion of vascular endothelial 
growth factor (VEGF), results 
in both increased vascular 
permeability and chaotic tu-
mour-vessel architecture. In 
combination, these effects 
cause enhanced permeation and 
retention (EPR) [16], result-
ing in high local drug con-
centrations (Figure 2). Key 
properties of any nanomateri-
al used in drug delivery are 
its biocompatibility and bi-
odegradability, so that the 
unloaded carrier is degraded 
or metabolized into non-tox-
ic components and cleared 
through the circulation. Ma-
terials are cleared accord-
ing to their size. Small 
particles (0–30 nm) are rap-
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idly cleared by renal excre-
tion. Nanocarriers >30 nm are 
cleared by the mononuclear 
phagocytic system (MPS), con-
sisting of macrophages locat-
ed in the liver (Kupffer cells) 
and the spleen [17], which 
act as phagocytotic scaven-
gers. Clearance is also de-
pendent on endothelial fenes-
tral size [17]. Fenestrae are 
highly variable, so it is dif-
ficult to determine the effica-
cy and toxicity of nanomedi-
cines in different individuals 
because age, sex and genetics 
influence their rate of clear-
ance [18]. Whether nanocarri-
ers are taken up by macrophag-
es depends on opsonization 
by the innate immune sys-
tem [19]. Opsonins, molecules 
that bind to foreign materi-
als and enhance phagocytosis, 
include IgG and IgA antibod-
ies, the complement cascade 
system and mannose-binding 
lectin [20]. Therefore, the 
surface properties of nano-
carriers can significantly af-
fect the rate of clearance by 
the MPS. A useful method for 
evading opsonization of large 
narrow carriers was devel-
oped in Rutgers University in 
the 1960s [21]: in a process 
called PEGylation, a polymer, 
poly(ethylene glycol) (PEG; 
[CH2CH2O]n), is conjugated to 
the drug carrier.
Overall, use of ligand–drug–
nanocarrier complexes im-
proves the drug therapeutic 
index. The high selectivi-
ty and specificity of the com-
plex, increases the amount of 
drug delivered to the tar-
get tissue and decreases the 
amount at unwanted sites. 
Therefore, less systemic drug 
needs to be administered to 
ensure a sufficient concentra-
tion at the site of action and 
the minimum efficacious dose 
is also lower. In addition, 
because less drug is present 
at unwanted sites, the maxi-
mum non-toxic is higher. The 
overall effect is a drastic 
decrease in toxicity and ad-
verse side effects [22].
1.2.1. Liposomes
Liposomes are closed spher-
ical vesicles consisting of 
one or more lipid bilayers 
that encapsulate an aqueous 
phase in which hydrophilic 
drugs can be stored while hy-
drophobic molecules can be 
dissolved into lipid bilay-
er. The size of liposome de-
pends on their composition 
and preparation method and 
can vary from approximately 
50 nm to greater than 1 μm 
in diameter. The lipid bilay-
er can be composed of either 
synthetic or natural phospho-
lipids. The predominant phys-
ical and chemical proper-
ties of liposomes are based 
on the net properties of the 
constituent phospholipids 
[24], including permeabili-
ty, charge density and ster-
ic hindrance. The lipid bi-
layer closes in on itself due 
to interactions between water 
molecules and the hydrophobic 
phosphate groups of the phos-
pholipids. This process of 
liposome formation is spon-
taneous because the amphi-
philic phospholipids self-as-
sociate into bilayers. Drug 
loading into liposomes can be 
achieved through (i) liposome 
formation in an aqueous solu-
tion saturated with soluble 
drug; (ii) the use of organic 
solvents and solvent exchange 
mechanisms; (iii) the use of 
lipophilic drugs; and (iv) pH 
gradient methods [25] (Figure 
3). Liposomes generally reach 
their site of action by ex-
travasation into the inter-
stitial space from the blood-
stream. Liposomes can target 
specific tissues through both 
active and passive targeting 
strategies (Figure 4). This 
is because they can easily be 
manipulated by linking addi-
tional molecules to the outer 
surface of the lipid bilayer. 
Liposomes are rapidly cleared 
by the MPS due to their size. 
Reducing opsonization of li-
posomes by PEGylation there-
fore reduces clearance by the 
MPS, increasing the circula-
tion half-life. Opsonization 
presents such a problem to 
the development of therapeu-
tically useful liposomes that 
nearly all research report-
ed in the literature involves 
PEG-coated or PEGylated li-
posomes. Liposomal formula-
tions of anticancer drugs 
have already been approved 
for human use. Doxil® is a 
liposomal formulation of the 
anthracycline drug doxoru-
bicin used to treat cancer 
in AIDS-related Kaposi sarco-
ma and multiple myeloma [26]. 
Its advantages over free dox-
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Figure 3 Diagram of a bilaminar liposome. The hydrophobic region traps drugs 
in the central core when the liposomes are prepared. The outer surface can be 
functionalized with ligands for active targeting or PEGylated. Liposomes can 
vary in the number of lipid bilayers they possess and can be classified into 
three categories: (i) multilamellar vesicles, (ii) large unilamellar vesicles 
and (iii) small unilamellar vesicles. Adapted from Ref. [29]
orubicin are greater effica-
cy and lower cardiotoxicity. 
These advantages are attrib-
uted to passive targeting of 
tumours, due to leaky tumour 
vasculature [27] and the EPR 
effect, and to lower concen-
trations of free doxorubicin 
at healthy tissue sites. 
There is evidence that lipos-
omal Doxil® is metabolized by 
leukaemia cells via a differ-
ent mechanism than that for 
free doxorubicin, which might 
explain the improved efficacy 
and lower toxicity. Further-
more, Doxil® is under clini-
cal trial for the treatment 
of breast cancer.
One of the most interesting 
developments in this field is 
the potential of liposomes to 
overcome the increasing prob-
lem of multidrug resistance 
(MDR) acquired by cancers, 
which drastically reduc-
es chemotherapeutic efficacy. 
Ogawara et al. recently in-
vestigated the effect of PEG 
liposomal doxorubicin (Dox-
il®) in a male mouse tumour 
model inoculated with either 
colon cancer (C26) cells or 
their doxorubicin-resistant 
(MDR) subclone, which over-
expresses P-gp efflux pumps 
[28]. The results showed 
that PEG liposomal doxoru-
bicin had anti-tumour effects 
on both doxorubicin-resistant 
and non-doxorubicin-resistant 
C26 cells. With increasing 
incidence of resistance to 
chemotherapy, the use of li-
posomes offers effective treat-
ment without the need for the 
costly discovery of new chem-
otherapeutic drugs because 
current drugs can be refor-
mulated. Liposomes are firmly 
established with the success 
of Doxil®, and new liposo-
mal formulations of other an-
ticancer drugs are now being 
intensively explored to im-
prove chemotherapy outcomes 
and reduce toxicity.
1.3. Liver targeting
The liver is well known for 
its high drug uptake because 
of its first pass-effect and its 
prominent role in the metab-
olism and excretion of many 
compounds including therapeu-
tic drugs. It receives blood 
(oxygenated and deoxygenated) 
from the gut and heart via 
the portal vein and hepatic 
artery, respectively. Blood 
Hydrophilic head
Lipid soluble drug
Protective layer (PEG)
Targeting ligand
DNA
Drug
Hydrophobic tail
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circulates through a perme-
able discontinuous capillary 
network term as the sinusoids 
to reach the central and he-
patic veins (Figure 4). The 
sinusoids are small blood ves-
sels (5 to 10μm wide) between 
the radiating rows of hepat-
ocytes having fenestrations 
of size 100–150 nm (depend-
ing on the type of animal spe-
cies). They allow almost un-
restricted passage of plasma 
components to the perisinu-
soidal space, where the cords 
of parenchymal cells called 
as hepatocytes are situated. 
Inside the sinusoid capillar-
ies, the Kupffer cells are re-
sponsible for phagocytic ac-
tivity of the liver [30].
One of the most prominent 
cell types in the liver are 
obviously the hepatocytes. 
The strategic localization 
of hepatocytes combined with 
a high expression of many 
transporters and endocytotic 
receptors is often a driving 
force for the accumulation of 
xenobiotics in this cell type. 
Consequently, many drugs are 
taken up and cleared from the 
circulation by this cell type 
without any targeting system. 
However, although hepato-
cytes represent more than 80% 
of the total number of resi-
dent hepatic cells, uptake in 
other cell-types like Kupffer 
cells may occur as well, and 
high uptake of viruses, an-
tibodies or other biological 
compounds into these cells 
often leads to complete deg-
radation of such compounds 
[31,32], which in some cas-
es destroys their therapeu-
tic activity. It seems clear 
that although drugs do accu-
mulate rapidly in liver they 
simply do not accumulate in 
the proper intrahepatic cell-
type [33], thus for specific 
cell, there should be specif-
ic delivery system and li-
gand for targeting. There may 
be five different cells types 
present in liver for active 
targeting of drug, namely, 
(i) hepatocytes, (ii) Kupffer 
and sinusoidal endothelial 
cells, (iii) hepatic stellate 
cells (HSC), (iv) bile duct 
epithelial cells, and, in 
the presence of a neoplasia 
(v) hepatocellular carcinoma 
cells (Figure 5). In particu-
lar, strategies for hepato-
cytes-and hepatocellular car-
cinoma cells-selective drug 
targeting will be detailed in 
the following sections.
1.3.1. Delivery systems to 
hepatocytes
In several pathological con-
ditions, such as viral hepa-
titis (Hepatitis A, B or C), 
alcohol-induced steatohepa-
titis (ASH), non-alcohol-in-
duced steatohepatitis (NASH), 
some genetic diseases like 
Wilson’s disease, hemochroma-
tosis, α1antitrypsin deficien-
cy, and several other meta-
bolic disorders, hepatocytes 
represent the most relevant 
target cells. In all these 
conditions, hepatocytes are 
infected or damaged and they 
are directly involved in the 
pathogenesis of these diseas-
es. Drug uptake by this par-
ticular cell-type is in gen-
eral not a major issue due to 
the first pass effect and the 
presence of many transport-
ers and endocytotic recep-
tors that take up drugs. In 
the past decades, many meth-
ods for hepatocyte-selective 
drug targeting have been ex-
plored in order to enhance the 
therapeutic effects of sever-
al antitumoral, antiviral and 
gene-based therapies or to 
reduce side-effects of antivi-
ral or anticancer drugs [33]. 
In most cases, the asialogly-
coprotein receptor (ASGP-R) 
has been used as the target 
receptor for drug delivery 
to the hepatocytes. Galac-
tose residues [35,36] or lac-
tose moieties [37] have been 
coupled to proteins, polymers 
or incorporated into the out-
er layer of liposomes [38]. 
The asialoglycoprotein recep-
tor is specifically and abun-
dantly present on hepatocytes 
[35–37,39] and this recep-
tor has been used to deliver 
all kinds of therapeutic com-
pounds ranging from therapeu-
tic proteins, antiviral agents 
[40] to anticancer drugs into 
hepatocytes [41–43]. In par-
ticular, ASGP-R-targeted li-
posomes have been widely used 
for the delivery of drugs, 
genes and oligonucleotides to 
this cell type. Indeed, de-
livery of liposomes and pro-
teins to the hepatocytes us-
ing this ASGP-R as a target 
receptor was one of the first 
options for the cell-specific 
delivery to liver cells, and 
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Figure 5 Receptors or cellular targets on liver cells for nanoparticles active-
ly targeting the liver. After intravenous administration, nanoparticles modified 
with specific surface ligands could be recognized by their receptors or cellu-
lar targets on a specific type of liver cells ((A) hepatocyte. (B) Hepatocellu-
lar carcinoma cell. (C) Hepatic stellate cells (HSC). (D) Kupffer cell. (E) En-
dothelial cells), and then the drug/gene was released. Adapted from Ref. [34]
Figure 4 Mechanisms of nanoparticles passively targeting the liver. (A) Micro-
scopic structure of liver sinusoid in hepatic lobules. (B) Nanoparticles small-
er than 3 nm in diameter could extravasate different tissues nonspecifically. (C) 
Nanoparticles with large negative surface charge or larger than 150 nm in di-
ameter could be captured by Kupffer cells. (D) Nanoparticles less than 200 nm in 
diameter could pass through sinusoidal fenestrations after intravenous admin-
istration. (E) Nanoparticles with negative surface charge tend to be taken up 
by Kupffer cells and endothelial cells. (F) Nanoparticles with positive surface 
charge tend to be taken up by hepatocytes. Adapted from Ref. [34]
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even to date, much research 
in the liposomal drug deliv-
ery area is still dedicated 
to targeting to this ASGP-R on 
hepatocytes [39,44], although 
this has not led to any clini-
cal application yet. ASGP-re-
ceptor ligands have also been 
applied for the delivery of 
siRNA to hepatocytes [45,46].
 
1.3.2. Delivery systems to 
hepatocellular carcinoma 
cells
In well-differentiated HCC 
cells, asialoglycoprotein 
(ASPG) receptor is highly ex-
pressed [47]. Several drug 
delivery systems have al-
ready been developed to de-
liver drugs to this receptor 
using lactosaminated or ga-
lactosamine substituted drug 
carriers. In particular, pol-
ymers have been applied for 
the purpose of drug delivery 
to HCC [42,48,49] but modified 
albumins have also been ex-
plored [50,51]. The ASGP-re-
ceptor has also been employed 
as a target receptor for the 
delivery of genes with an-
tineoplastic effects to the 
hepatocytes by making com-
plexes of plasmids and pol-
ymers coupled to ASGP-recep-
tor binding ligands [52,53]. 
Moreover, other drug delivery 
systems such as cationic li-
posomes, virosomes, and ade-
noviral vectors have been ex-
ploited for the delivery of 
anticancer drugs and genes in 
HCC. Cheng et al. [54] synthe-
sized GC/5-FU nanoparticles 
by combining galactosylat-
ed chitosan (GC) material 
with 5-FU, and tested its ef-
fect on liver cancer cells in 
vitro and in vivo. They con-
cluded that sustained releas-
es of GC/5-FU nanoparticles 
are more effective in target-
ing hepatic cancer cells than 
5-FU monotherapy, as shown in 
mouse orthotropic liver can-
cer model. In the same year, 
Li et al. [55] stated that the 
encapsulation of tetrandrine 
(Tet) and paclitaxel (Ptx) 
into nanoparticles retain the 
synergistic anticancer effi-
ciency of Tet and Ptx against 
mice hepatoma H22 cells. Oth-
er researchers, Zhou et al. 
[56], synthesized N-lacto-
syl-ioleoylphosphatidyletha-
nolamine (Lac-DOPE) and eval-
uated it as a liver-specific 
targeting ligand via ASGP-R 
receptors for liposomal de-
livery of doxorubicin. It re-
ported that lactosylated li-
posomes are promising drug 
delivery vehicles for hepa-
tocellular carcinoma. Re-
cently, Zhang et al. [57] 
reported that mixed copol-
ymer nanoparticles (NPs), 
self-assembled from β-cyclo-
dextrin-grafted hyperbranched 
polyglycerol (HPG-g-CD) and 
lactobionic acid (LA)-graft-
ed hyperbranched polyglycer-
ol (HPG-g-LA), were utilized 
as carriers for paclitaxel, 
resulting in enhanced hepa-
tocellular-carcinoma up-
take of these nanoparticles. 
Therefore, it was conclud-
ed that mixed copolymer NPs 
are efficient nanocarriers for 
hepatoma-targeted delivery of 
potent antitumor drugs.
To enhance the specificity for 
HCC, other targeting strat-
egies using monoclonal an-
tibodies (mAb), and growth 
factor-recognizing oligopep-
tides have been utilized. The 
HCC-specific monoclonal anti-
body AF-20, directed against 
a 180 kDa-cell-surface glyco-
protein which is highly ex-
pressed on HCC [58] has been 
explored, but recently re-
search focused on the use 
of antibodies against growth 
factor receptors that are ex-
pressed on HCC. Similar to 
other tumors, HCC tissues ex-
press epidermal growth fac-
tor (EGF) receptors and a 
chimeric (mouse/human) anti-
body against this EGF-recep-
tor (Cetuximab) has been ex-
amined in clinical trials 
[59,60]. Several studies show 
that this antibody is bene-
ficial in patients with HCC 
and may be used in combina-
tion with other drugs. Howev-
er, antibodies have not been 
applied as drug carrier to 
HCC. For that purpose oligo-
peptides recognizing the EGF 
receptor have been used. Liu 
et al. and Lee et al. both 
applied an EGFR-binding pep-
tide for gene delivery to HCC 
[61,62]. Liu et al. demon-
strated that delivery of hu-
man cyclin-dependent kinase 
inhibitor gene p21WAF-1 and 
murine cytokine gene GM-CSF 
using EGF receptor oligopep-
tides produced potent antitu-
mor effects in hepatoma-bear-
ing mice [61], and beneficial 
effects were also obtained us-
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ing EFG itself as homing li-
gand [63]. Although many of 
HCC targeted cell-selective 
therapies applied an intra- 
or peri-tumor inoculation of 
the compounds [62], Liu et 
al. demonstrated beneficial ef-
fects after systemic adminis-
tration of the EGF-R target-
ed genes [64]. The use of the 
EGF ligand itself to direct 
compounds to the EGF-receptor 
was applied by Wolschek et 
al. They used these compounds 
to deliver the reporter gene 
beta-galactosidase into HCC 
after systemic administration 
into mice [63]. 
Significant tumor accumulation 
of drugs can already be ob-
tained in patients with HCC 
based on the enhanced perme-
ability and retention (EPR) 
effect [65] if a drug deliv-
ery tool with the proper mo-
lecular size is used. Com-
bined with a HCC-selective 
molecule, additional cell-se-
lectivity and thus therapeu-
tic effectiveness may be ob-
tained. In the area of drug 
targeting to HCC, significant 
advancement has been made in 
recent years, leading to an 
improved management of HCC in 
patients.
1.3.3. Lactoferrin as ligand 
for liver targeting
In order to enhance the tar-
geting efficiency of drug de-
livery systems to receptors 
in hepatocytes, several novel 
materials have been employed 
and, among them, we have se-
lected Lactoferrin (Lf). It 
is a mammalian cationic iron 
binding glycoprotein belong-
ing to the transferrin (Tf) 
family [66]. Recently this 
glycoprotein is becoming in-
creasingly attractive be-
cause of its multifunction-
al and mediating biological 
activities with Lf receptors 
(Lf-R) [67,68]. Formerly Lf-R 
was successfully utilized as 
a targeting ligand for brain 
delivery due to the pres-
ence of Lf receptor on blood 
brain barrier (BBB) [69–71]. 
Likewise, many recent stud-
ies revealed that lactoferrin 
could bind to multiple recep-
tors on hepatocytes prior to 
internalization, including 
low-density lipoprotein re-
ceptor-related protein recep-
tors (LRP-R) [72,73] and the 
asialoglycoprotein receptors 
(ASGP-R) [74,75], which also 
belong to LfR [67,76,77]. It 
has been demonstrated that Lf 
binds ASGP-R with high affin-
ity (Kd approx. 80 nM) in a 
galactose-independent manner 
[78], implying Lf is a good 
ligand to ASGP-R binding. For 
instance, Wei et al. reported 
Lf-PEGylated liposomes (PLS) 
as a promising drug deliv-
ery system for hepatocellular 
carcinoma therapy with low-
er toxicity and enhanced ef-
ficacy [79]. It has been val-
idated that Lf-R binds to 
ASGP-R with high affinity, im-
plying that Lf-R is a good 
ligand to ASGPR binding. Due 
to its specific binding, Lf-R 
has been applied to gene de-
livery successfully, for the 
transfer of genetic materi-
al to the hepatocytes [80]. 
These exciting evidences sug-
gested that Lf-R might be a 
promising candidate for hepa-
tocellular carcinoma target-
ing due to its high affini-
ty for ASGP-R, and that is 
highly possible to develop 
a hepatic carcinoma target-
ing drug delivery system em-
ploying the ASGP-R targeting 
ability of Lf-R.
2. The aim of the work
Given the T3 anticancer po-
tential in the treatment of 
hepatocellular carcinoma, the 
aim of this work was to devel-
op an effective hepatocellular 
carcinoma targeting drug de-
livery system to improve the 
T3 delivery to hepatic cancer 
cells and, at the same time, 
to reduce toxic side effects. 
Three different liposome sys-
tems, such as, convention-
al, Stealth (PEGylated) and 
Lf-modified-Stealth liposomes 
were developed and character-
ized. Liposomes cell inter-
actions and cellular uptake 
were evaluated in FaO, HepG2 
and SKHep cells by confocal 
microscopy using liposomes 
labeled with the lipophilic 
marker 1,2-dioleolylsn-glyce-
r o - 3 - p h o s p h o e t h a n o l a -
mine-N-(lissamine rhodamine B 
sulfonyl) (Rho-PE) and load-
ed with the hydrophilic probe 
5(6)-carboxyfluorescein (CF). 
Finally, in vitro cytotoxic-
ity studies were carried out 
by using MTT assay to evalu-
ate the toxicity of the li-
posome delivery system and to 
test the effect of T3 when in-
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corporated into liposomes.
 
3. Materials and methods
3.1 Materials
1-Palmitoyl-2-oleylphospha-
tydilcholine (POPC), di-
methyldioctadecylammonium 
(DDAB), DSPE-PEG-maleimide 
and 1,2-dioleolylsn-glyce-
r o - 3 - p h o s p h o e t h a n o l a -
mine-N-(lissamine rhodamine 
B sulfonyl) (Rho-PE) were 
purchased from Avanti Po-
lar Lipids (Alabaster, USA). 
1,2-distearoyl-sn-glyce-
r o - 3 - p h o s p h o e t h a n o l a -
mine-N-[methoxy (polyethylene 
glycol)-2000]-(DSPE-PEG2000) 
was purchased from Lipoid 
GmbH (Ludwigshafen, Germa-
ny). Phosphate buffer solution 
(PBS, pH 7) was purchased from 
Carlo Erba Reagents (Rodano, 
Italy). 3,3′,5-Triiodo-L-thy-
ronine sodium salt (T3), 
2-iminothiolane (Traut’s re-
agent), Lactoferrin, from bo-
vine colostrum (Lf), Sepharose 
CL-4B, 5(6)-carboxyfluores-
cein (CF) and all the other 
products were purchased from 
Sigma–Aldrich (Milan, Ita-
ly). Centriprep-30 (molecular 
weight cut-off: 30,000) con-
centrators were from Amicon 
(Billerica, Massachusetts). 
3.2. Liposomes preparation
All liposome formulations 
were prepared according to 
the film hydration method. 
Conventional liposomes (Conv-
LIPO) were obtained by dis-
solving in a chloroform/
methanol (1/1, v/v) mixture 
POPC (78.94 μmol) (1-Palmi-
toyl-2-oleylphosphatydilcho-
line), DDAB (0.63μmol) (Di-
methyldioctadecylammonium) 
and T3 (10 μmol) (as metha-
nol solution). By adding to 
this mixture DSPE-PEG2000 
(2.4 μmol)(1,2-distea-
royl-sn-glycero-3-phosphoe-
thanolamine-N-[methoxy (pol-
yethylene glycol)-2000] and 
the linker lipid DSPE-PEG- 
maleimide (0.72 μmol) Stealth 
liposomes (Stealth-LIPO) 
and targeted liposomes (Lf-
Stealth-LIPO) were respec-
tively produced. The lipid 
mixtures were deposited as 
a thin film in a roundbottom 
flask by rotoevaporating (Ro-
tavapor Büchi R110, Flawil, 
Switzerland) the chloroform/
methanol under vacuum. The 
thin lipid films were hydrat-
ed at 65°C with 1 mL of PBS 
at room temperature. Thiolat-
ed Lf solutions were concen-
trated and the buffer exchanged 
with phosphate buffer solution 
using a Centriprep-30 con-
centrator (molecular weight 
cut-off: 30,000, Amicon). The 
concentrated lactoferrin was 
immediately added to the ma-
leimide grafted liposomes and 
left to react overnight at 
room temperature. Lastly, the 
lactoferrin-conjugated lipos-
omes were separated from T3 
and free Lf by Sepharose CL-
4B gel filtration as described 
above [81].
3.4. Liposomes characteriza-
tion
3.4.1. Particle size and zeta 
potential
Size distribution (average 
diameter and polydispersi-
ty index (PI)) of the sam-
ples was determined by pho-
ton correlation spectroscopy 
using a Zetasizer nano (Mal-
vern Instrument, Worcester-
shire, United Kingdom). Be-
fore counting, the samples 
were diluted with PBS. Sam-
ples were backscattered by 
helium–neon laser (633 nm) at 
an angle of 173° and at con-
solution (pH 7) by mechanical 
shaking for 2 h. The result-
ing liposome dispersions were 
sonicated with a Soniprep 150 
ultrasonic disintegrator (MSE 
Crowley, London, United King-
dom) until a clear opales-
cent dispersion was obtained 
(5 seconds on and 2 seconds 
off, 60 cycles). The liposomes 
were then purified on a Sepha-
rose CL-4B gel filtration col-
umn using phosphate buffer as 
eluent.
3.3. Lactoferrin conjugation
To prepare targeted liposomes 
(Lf-Stealth-LIPO), Lactofer-
rin was conjugated to the li-
posome by means of thioether-
bonds between the protein and 
the linker lipids of the li-
posomes. Here, the Lf mole-
cules are thiolated using 
2-iminothiolane (Traut’s re-
agent) and react with the ma-
leimide groups on the PEG ter-
minus. Then, 3.38 mg/ml (42,3 
nmol) Lf was added to 2 ml 
borate–EDTA buffer (0.15 M Na 
borate, 0.1 mM EDTA, pH 8.5) 
containing 1692 nmol of fresh 
Traut’s reagent. This mixture 
was incubated for 60 min on a 
rotational shaker (at 110 rpm) 
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stant temperature of 25°C. 
Zeta potential was estimated 
using the Zetasizer nano by 
means of the M3-PALS (phase 
analysis light scattering) 
technique, which measures 
the particle electrophoret-
ic mobility in a thermostated 
cell. A long-term stability 
study of formulations stored 
at 4 ± 1°C was performed by 
monitoring the vesicle aver-
age size, polydispersity in-
dex and surface charge over 
90 days.
3.4.2. Encapsulation efficien-
cy
Encapsulation efficiency (E%), 
expressed as the percentage 
of the encapsulated drug re-
spect to the amount of T3 in-
itially used in liposomal 
preparation, was determined 
by gel filtration chromatog-
raphy. Briefly, 800 µl of the 
samples were loaded on a Se-
pharose CL-4B column which 
was pre-equilibrated with PBS 
buffer and then eluted with 
the buffer. T3 loaded lipos-
omes were collected and di-
luted with methanol. T3 con-
tent was quantified by HPLC 
method.
3.4.3. Transmission Electron 
Microscope (TEM)
The morphological character-
istics of the liposomes were 
examined using a Transmission 
Electron Microscope (TEM). 
Liposomes were deposited for 
2 minutes on carbon coat-
ed 200 mesh copper grids and 
negatively stained with 2.5% 
uranyl acetate for 2 minutes, 
washed with water, drained 
and observed at 80 kV with a 
Tecnai 12 (Fei) TEM.
3.4.4. HPLC analysis for T3
T3 content was quantified at 
226 nm using a chromatograph 
Alliance 2690 (Waters, Milan, 
Italy), equipped with a pho-
todiode array detector and a 
computer integrating appa-
ratus (Empower 3). The col-
umn was a SunFire C18 (3.5 
μm, 4.6 mm × 100 mm, Waters), 
and the mobile phase was a 
mixture of water, methanol, 
acetonitrile and acetic acid 
(41.92:40:18:0.08, v/v), de-
livered at a flow rate of 0.7 
ml/min.
A standard calibration curve 
was built up by using working, 
standard solutions. Calibra-
tion graphs were plotted ac-
cording to the linear regres-
sion analysis, which gave a 
correlation coefficient value 
(R2) of 0.999.
3.5. Cell experiments
3.5.1. Cell line culture 
FaO, rat hepatoma cell line 
and human hepatocarcinoma 
cell line, HepG2, were sup-
plied by Interlab Cell Line 
Collection (Servizio Biotec-
nologie, IST, Genova, Italy) 
and maintained in Dulbecco’s 
medium (DMEM plus Glutamax I) 
(Invitrogen). The liver hu-
man cells SKHep were a gen-
tle gift from Prof. Silvia 
Giordano (Istituto Oncologico 
Candiolo, Torino, Italy) and 
were maintained in Minimun Es-
sential Medium (Invitrogen). 
Both culture medium, DMEM and 
MEM, were supplemented with 
penicillin, streptomycin and 
10% heat-inactivated fetal 
calf-serum (FCS) (Invitrogen) 
and the cells maintained in 
a humidified atmosphere of 5% 
CO2/95% air, at 37°C. After 19 
hours of incubation, the me-
dium was replaced with fresh 
medium without serum and the 
cells were treated with dif-
ferent concentration of empty 
and drug loaded formulations 
as indicated in the figures.
3.5.2. Western Blot Analysis
After treatment, total pro-
tein extracts were obtained 
using M-PER Mammalian Protein 
Extraction Reagent (Thermos 
Scientific, Rockford, IL, USA) 
plus Halt Protease Inhibitor 
Cocktail (Thermo Scientif-
ic) and according to manufac-
turer’s instruction. Protein 
concentration of the total 
extracts was determined ac-
cording to the method of Brad-
ford [82] using BSA as stand-
ard (DC Protein Assay, Bio 
Rad Laboratories, Hercules, 
CA). For immunoblotting anal-
ysis, equal amounts of pro-
teins were electrophoresed 
on SDS 10% polyacrilamyde 
gels. After gel electrotrans-
fer onto nitrocellulose mem-
branes, to ensure equivalent 
protein loading and transfer 
in all lanes, the membranes 
were stained with 0.5% (w/v) 
Ponceau S red (ICN Biomedi-
cals) in 1% acetic acid for 
5 minutes. After blocking in 
TBS containing 0.5% Tween 20 
(Sigma) (TBS-T) and 5% non-
fat dry milk for 1 hour at 
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room temperature or over-
night at 4° C, membranes were 
washed in TBS-T and incubat-
ed with the appropriate pri-
mary antibodies diluted in 
blocking buffer. Whenever pos-
sible, the same membrane was 
used to detect the expression 
of different proteins. Depend-
ing on the origin of primary 
antibody, filters were incu-
bated with anti-mouse, an-
ti-goat or anti-rabbit horse-
radish peroxidase-conjugated 
IgG (Santa Cruz Biotechnolo-
gy, Santa Cruz, CA). Immuno-
reactive bands were identified 
by chemiluminescence detec-
tion system, as described by 
the manufacturer (Supersig-
nal Substrate, Pierce, Rock-
ford, IL). For immunoblotting 
experiments mouse monoclonal 
anti-actin (clone AC-40, Sig-
ma) and Thyroid Hormone Re-
ceptor beta-1 (J52, Thermo 
Scientific) antibodies were 
used. 
3.5.3. Cellular uptake of flu-
orescent liposomes
Cell interactions and cellu-
lar uptake were investigat-
ed by confocal microscopy us-
ing liposomes labeled with a 
lipophilic fluorescent mark-
er 1,2-dioleolyl-sn-glyce-
r o - 3 - p h o s p h o e t h a n o l a -
mine-N-(lissamine rhodamine 
B sulfonyl) (0.035 mg/ml; 
RhoPE) and loaded with a hy-
drophilic fluorescent marker 
5(6)-carboxyfluorescein (0.025 
mg/ml; CF). Liposomes were pu-
rified from the non-entrapped 
markers by gel filtration as 
described above. Cells (3 x 
105/3ml medium) were grown in 
collagen coated slides seat-
ed in 6 wells plate, and the 
experiments were performed to 
the achievement of subconflu-
ence. FaO, HepG2 and SKHep 
cells were incubated at 37°C 
with the different formulation 
and a solution of CF for 1 and 
3 hours at the highest con-
centration used for the cy-
totoxicity study (1:100). At 
the end of the experiment, 
the cells were washed twice 
with PBS (EuroClone, Italy) 
and fixed with a solution of 
4% buffered formaldeyde (pH 
7.4) (Sigma, Milan, Italy) 
and treated with triton X-100 
(0.1%, Sigma, Milan, Italy) 
to increase the permeability 
of the cells. The fixed cells 
were washed with PBS and then 
stained with Hoechts 33258 
blue (Life Technologies, In-
vitrogen, Milan, Italy) to 
display the nucleus. Af-
ter staining, the cells were 
again washed with PBS and were 
mounted with Mounting Medium 
(BioSystem, Italia). 
The fluorescence images were 
analyzed with the laser scan-
ning confocal microscope 
(FluoView, FV10i, Olympus). 
CF, RhoPE and Hoechst 33258 
fluorescence was observed with 
470 ± 20/535 ± 40, 546 ± 6/620 
± 60 and 360 ± 20/460 ± 25 
excitation/emission filters 
respectively.
3.5.4. Cell viability studies 
The toxic effect of liposomes 
was determined by the cell 
viability MTT (tetrazoli-
um salt, 3-(4,5-dimethylthi-
azol-2yl)-2,5-diphenyltetra-
zolium bromide) assay. 200 mL 
of 1:10 diluted MTT stock (5 
mg/mL of MTT in Hanks’ bal-
anced salt solution) was add-
ed to each culture. The formed 
crystals were solubilized in 
a solution of isopropanol-10% 
NP40-0.4N HCl, and absorb-
ance values were measured at 
the wavelength of 570 nm with 
the background subtraction 
at 690 nm in a Packard Spec-
tra Count microplate reader 
(Packard Instrument Co, Down-
ers Grove, IL). Cells (2 x 
104 cells/well) were seeded 
in 96 well plates with 200 μl 
of culture medium. Nineteen 
hours after seeding the me-
dium was replaced with fresh 
medium without FCS, and cells 
were treated with both emp-
ty and drug loaded formula-
tions at different dilutions 
(1:100, 1:200, 1:400, 1:800, 
1:1600 for empty formulations 
and 1:100, 1:200, 1:1000 for 
T3 loaded formulations). In 
parallel, hepatoma cells were 
treated with T3 solutions at 
different dilutions (1:100, 
1:200, 1:1000). T3 was dis-
solved in 1N NaOH and neu-
tralized with cultured medi-
um. Each sample was tested 
in triplicate for at least 
three times. The untreated 
cells were used as negative 
control.
  
3.6. Statistical analysis of 
data
Instat software (GraphPad 
Prism4, San Diego, CA) was 
used to analyze the data. 
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Figure 6 Schematic representation of conventional liposomes (Conv-LIPO), stealth 
liposomes (Stealth-LIPO) and liposomes conjugated to lactoferrin (Lf-Stealth-
LIPO) and schematic preparation and covalent attachment of Lf to stealth li-
posome surface.
One-way analysis of variance 
(ANOVA) with post hoc anal-
ysis using Tukey’s multiple 
comparison test was used for 
parametric data. The results 
of multiple observations were 
presented as the means ± S.D 
of at least 3 separate exper-
iments. A p value of <0.05 
was considered statistically 
significant.
4. Results and discussion
4.1. Preparation and char-
acterization of empty and 
drug-loaded liposomes
Liposomes (see Figure 6 for 
schematic representation) 
were successfully prepared 
using the film hydration meth-
od. As shown in Table 1, six 
different formulations were 
prepared. Empty and drug load-
ing conventional liposomes 
(Conv-LIPO) were prepared us-
ing only POPC and DDAB. Then, 
the outer surface of lipos-
omes was modified by adding a 
pegylated lipid (DSPE-PEG) to 
the composition of conven-
tional formulation (Stealth-
LIPO). Finally, for the 
preparation of targeted li-
posomes (Lf-Stealth-LIPO) the 
lipid linker DSPE-PEG-maleim-
ide was incorporated in the 
lipid mixture. Lf was cova-
lently conjugated to the dis-
tal end of DSPE-PEG- maleim-
ide lipid by thioether bond 
and loaded onto Stealth li-
posomes surface as targeting 
moiety. To bind the linker 
with a thioether bond Lf was 
thiolated using 1:40 Lf/imi-
nothiolane molar ratio [81].
Liposomes TEM visualization 
(Figure 7) shows multi-lamel-
lar vesicles, small in size 
and with spherical shape. The 
physical properties of li-
posomes are shown in Table 
2. PCS measurements showed a 
mean diameter of empty and T3 
loaded-formulations ranging 
between 86 and 126 nm, which 
are preferable for tumor ac-
cumulation via the EPR effect 
[23]. Polydispersity index (≤ 
0.28) proved a fairly narrow 
size distribution for all the 
formulations. However, empty 
and T3 liposomes were slight-
ly increased in size after 
incubation with Lf (126.5 and 
103.1 nm), while PI values 
did not show any significant 
variation after the Lf at-
tachment. The zeta potential 
analyses showed that all li-
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Formulations  Components (µ mol)   
 T3   POPC   DDAB   DSPE-PEG   
DSPE-PEG-
Maleimide  
Lactoferrin  
Conv-LIPO  78.94 0.63 - - - 
T3-Conv-LIPO 10 78.94 0.63 - - - 
Stealth-LIPO - 78.94 0.63 2.4 - - 
T3-Stealth-LIPO 10 78.94 0.63 2.4 - - 
Lf-Stealth-LIPO - 78.94 0.63 2.4 0.72 0.043 
T3-Lf-Stealth-LIPO 10 78.94 0.63 2.4 0.72 0.043 
MD (nm) 
         
PI ZP (mV)
 
E % 
Conv-LIPO empty 98.1 ± 1.04 0.28 ± 0.01 5.7 ± 0.22  
 T3 86.8 ± 0.66 0.28 ± 0.02 7.5 ± 2.37 91 ± 3.1 
Stealth-LIPO empty 94.6 ± 1.53 0.20 ± 0.03 2.5 ± 0.41  
 T3 99.4 ± 0.77 0.23 ± 0.02 1.3 ± 0.03 87 ± 4.2
Lf-Stealth-LIPO empty 126.5 ± 2.58 0.25 ± 0.03 1.2 ± 0.55  
 T3 103.1 ± 1.16 0.17 ± 0.02 1.1 ± 0.35 90 ± 3.2
Table 1 Composition of empty and T3 loaded-Conventional (Conv-LIPO), Stealth 
liposomes (Stealth-LIPO) and Lf-modified-Stealth liposomes (Lf-Stealth-LIPO).
Table 2. Liposomes physicochemical characterization. Average diameter (MD), 
polydispersity index (PI), zeta potential (ZP) and Encapsulation Efficiency (E%) 
of freshly prepared liposomal formulations. Values are the means ± standard de-
viation (n = 3).
A
100 nm
B
100 nm
Figure 7 TEM micrographs of T3-loaded conventional and stealth liposomes: Conv-
LIPO (a) and Stealth-LIPO (b) 
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Figure 8 Average diameter (Z-average) and polydispersity index (PI) of T3 load-
ed liposomal formulations monitored during 90 days of storage at 4 °C.
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Figure 9 a)Western blot analysis of TRβ in HepG2, FaO and SKHep cells. Western 
analysis was performed as described in Materials and Methods. Actin was used 
as a loading control. b) Densitometric quantification of TRβ in HepG2, FaO and 
SKHep cells compared to actin (TRβ/Actin)
posomes possessed nearly neu-
tral surface charges (≤7.5 
mV), which could reduce un-
desirable nonspecific protein 
adsorption [83]. The encap-
sulation efficiency (EE) of 
T3 loaded liposomes was rel-
atively high, approximately 
90%, thus demonstrating that 
the presence of the ligand 
did not influence the liposome 
ability to include the drug.
Physical stability is an im-
portant parameter for in 
vivo biomedical application 
of liposomes. In this study 
the physical stability of 
drug-loaded liposomes was in-
vestigated by monitoring var-
iations in size distribution 
during time. As shown in Fig-
ure 8, all liposomes were 
stable over 90 days at 4°C 
and only a slight increase in 
size was observed for Conv-
LIPO and Stealth-LIPO. Howev-
er, after 90 days the mean 
diameter of all the studied 
vesicles was below130 nm.
4.2. Cell studies
In this study rat hepatoma, 
FaO, human hepatocarcinoma, 
HepG2 and SKHep, cell lines 
have been chosen as HCC tar-
get cells. 
First of all, the Thyroid 
Hormone Receptor β-1 (TRβ) 
expression has been checked 
in the selected cell lines. 
It is known that T3 performs 
its action through interac-
tion with its nuclear recep-
tors (TRs) among which, TRβ 
form is predominant in liv-
er and it is responsible for 
the hepatomitogenic activity 
of T3 [7].
TRβ expression was analyzed 
by Western Blot analysis us-
ing actin as loading control 
and densitometric analysis 
was also performed to quanti-
fy TRβ expression. As shown in 
Figure 9, the TRβ protein ex-
pression was observed in all 
the tested cell lines (Fig-
ure 9.a) with the highest ex-
pression detected in HepG2 
(approximately 4 fold high-
er than that observed in FaO 
and SKHep cell lines) (Fig-
ure 9.b).
4.2.1. Cell binding and cel-
lular uptakes of liposomes
The internalization of li-
posomes into the target 
cells was analyzed by confo-
cal microscopy. To this pur-
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Figure 10a Confocal microscopy images of FaO cells treated with Rho and CF load-
ed liposomal formulations. FaO cells were incubated with Conv-LIPO for 3h at 37 
°C. Cell nuclei were stained blue with Hoechst and the localisation and inten-
sity of dyes are displayed in red for Rho, in green for CF. 
pose, FaO, HepG2 and SKHep 
cells were incubated for 1 
and 3 hours with Lf-Stealth-
LIPO, Conv-LIPO and Stealth-
LIPO, containing two fluores-
cent markers: one lipophilic, 
rhodamine (0.035 mg/ml Rho) 
and one hydrophilic, (6)-car-
boxyfluorescein (0.025 mg/
ml, CF). CF was chosen be-
cause it is a membrane im-
permeable probe largely used 
for investigating membrane 
integrity and permeabili-
ty [84,85]. After treatment 
with liposome formulations, 
the cells were fixed, and the 
Hoechst dye, which allows the 
visualization of the nucle-
us, was added. The images ob-
tained for each marker were 
overlapped to simultaneously 
display the location of each 
marker inside the cells. Fig-
ures 10.a, 10.b, 10.c, 11.a, 
11.b, 11.c, 12.a, 12.b, 12.c, 
show the fluorescence imag-
es of FaO, HepG2 and SKHep 
cells treated with liposomes 
after 3 hours incubation, in 
which it is clear that the 
markers were internalised. In 
particular, orange fluores-
cence intensity, due to the 
merging of red-rhodamine and 
green-CF, was higher in cells 
treated with Lf-Stealth-LIPO 
compared to that detected in 
FaO, HepG2 and SKhep cells af-
ter treatment with Conv-LIPO 
and Stealth-LIPO. Further-
more, a progressive time-de-
pendent increase of orange 
fluorescence intensity in all 
three cell lines after treat-
ment with Lf-Stealth-LIPO was 
observed (Figures 13, 14, 
15). By contrast, this phe-
nomenon does not occur when 
using conventional or Stealth 
liposomes. These results sug-
gested that cell binding and 
cellular uptake of Lf-lipos-
omes and non-targeted lipos-
omes (Conv-LIPO and Stealth 
-LIPO) were different. Lf-
Stealth-LIPO might marked-
ly enhance the specific cell 
binding and cellular uptake 
in hepatoma cells due to the 
mediating of Lf that could 
bind to multiple receptors on 
cell surface such as ASGP-R 
with high affinity [79].
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Figure 10c Confocal microscopy images of FaO cells treated with Rho and CF load-
ed liposomal formulations. FaO cells were incubated with Lf-Stealth-LIPO (c) 
for 3h at 37 °C. Cell nuclei were stained blue with Hoechst and the localisation 
and intensity of dyes are displayed in red for Rho, in green for CF. 
Figure 10b Confocal microscopy images of FaO cells treated with Rho and CF load-
ed liposomal formulations. FaO cells were incubated with Stealth-LIPO for 3h at 
37 °C. Cell nuclei were stained blue with Hoechst and the localisation and in-
tensity of dyes are displayed in red for Rho, in green for CF. 
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Figure 11b Confocal microscopy images of HepG2 cells treated with Rho and CF 
loaded liposomal formulations. HepG2 cells were incubated Stealth-LIPO for 3h 
at 37 °C. Cell nuclei were stained blue with Hoechst and the localisation and 
intensity of dyes are displayed in red for Rho, in green for CF.
Figure 11a Confocal microscopy images of HepG2 cells treated with Rho and CF 
loaded liposomal formulations. HepG2 cells were incubated with Conv-LIPO for 3h 
at 37 °C. Cell nuclei were stained blue with Hoechst and the localisation and 
intensity of dyes are displayed in red for Rho, in green for CF.
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Figure 12a Confocal microscopy images of SKHep cells treated with Rho and CF 
loaded liposomal formulations. SKHep cells were incubated with Conv-LIPO for 3h 
at 37 °C. Cell nuclei were stained blue with Hoechst and the localisation and 
intensity of dyes are displayed in red for Rho, in green for CF.
Figure 11c Confocal microscopy images of HepG2 cells treated with Rho and CF 
loaded liposomal formulations. HepG2 cells were incubated with Lf-Stealth-LIPO 
for 3h at 37 °C. Cell nuclei were stained blue with Hoechst and the localisation 
and intensity of dyes are displayed in red for Rho, in green for CF
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Figure 12c Confocal microscopy images of SKHep cells treated with Rho and CF 
loaded liposomal formulations. SKHep cells were incubated with Lf-Stealth-LIPO 
(c) for 3h at 37 °C. Cell nuclei were stained blue with Hoechst and the local-
isation and intensity of dyes are displayed in red for Rho, in green for CF
Figure 12b Confocal microscopy images of SKHep cells treated with Rho and CF 
loaded liposomal formulations. SKHep cells were incubated with Stealth-LIPO for 
3h at 37 °C. Cell nuclei were stained blue with Hoechst and the localisation and 
intensity of dyes are displayed in red for Rho, in green for CF
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Figure 14 Confocal microscopy images of HepG2 cells treated for 1 e 3 hours 
with fluorescent liposomal formulations: Conv-LIPO (a), Stealth-LIPO (b) and 
Lf-Stealth-LIPO (c). Cell nuclei were stained blue with Hoechst and the orange 
fluorescence is due to the overlap of red-Rho and green-CF.
Figure 13 Confocal microscopy images of FaO cells treated for 1 e 3 hours with 
fluorescent liposomal formulations: Conv-LIPO (a), Stealth-LIPO (b) and Lf-
Stealth-LIPO (c). Cell nuclei were stained blue with Hoechst and the orange flu-
orescence is due to the overlap of red-Rho and green-CF.
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Figure 15 Confocal microscopy images of SKHep cells treated for 1 e 3 hours 
with fluorescent liposomal formulations: Conv-LIPO (a), Stealth-LIPO (b) and 
Lf-Stealth-LIPO (c). Cell nuclei were stained blue with Hoechst and the orange 
fluorescence is due to the overlap of red-Rho and green-CF.
4.2.2. In vitro toxicity 
studies
In order to investigate the 
toxicity of the liposome de-
livery system, target cells 
(FaO, HepG2 and SKHep cells) 
were used to evaluate the cell 
viability via MTT assay. The 
test is based on the ability 
of MTT to be metabolised by 
a mitochondrial enzyme, suc-
cinate dehydrogenase. The re-
duction of MTT leads to the 
formation of crystals of for-
mazan, a water insoluble 
blue/violet dye. Since viable 
cells reduce MTT, the amount 
of formazan produced is pro-
portional to their number. 
Cytotoxicity effects strong-
ly depend on different param-
eters such as phospholipid 
used, cell line, incubation 
times, serum-containing/free 
medium, ect [86]. Therefore, 
the serum-free conditions 
were chosen [79] and cells 
were treated with increasing 
concentrations of both empty 
and T3-containing liposomes 
(Conv-LIPO, Stealth-LIPO, and 
Lf-Stealth-LIPO) at different 
incubation time (24, 48 and 
72 hours). Outcomes of cito-
toxicity studies for the emp-
ty formulations are summa-
rized in Figures 16, 17, 18. 
The value obtained for treat-
ed cells was expressed as per-
centage of the value obtained 
in control cells (untreat-
ed). As shown in Figures 16, 
17, 18, treatment with differ-
ent concentrations of empty 
conventional (Conv-LIPO) and 
Lf-modified-Stealth liposomes 
(Lf-Stealth-LIPO) did not in-
duce statistically significant 
differences in the degree of 
toxicity in the time inter-
val between 24 and 72 hours in 
FaO (Figure 16), HepG2 (Fig-
ure 17) and SKHep (Figure 18) 
cells. By contrast, a low but 
significant loss of viability 
(∼20%) occurred already af-
ter 24 hours treatment in the 
presence of the higher con-
centration of empty Stealth 
liposomes (Stealth-LIPO) in 
all the analyzed cell lines 
(Figure 16b, Figure 17b, Fig-
ure 18b). In conclusion, our 
results indicated that all 
the empty liposome formula-
tions tested induced a very 
low citotoxic effect on hepato-
ma cell lines suggesting that 
they are safe carriers.
Afterwards, the effect of T3 
Conv-LIPO
1h
3h
Stealth-LIPO Lf-Stealth-LIPO
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incorporated into liposomes 
was investigated. Figures 19, 
20, 21 show the results of 
the cell viability test per-
formed in hepatoma cells us-
ing T3 loaded vesicles or a 
T3 solution. FaO, HepG2 and 
SKHep cells were treated with 
different concentrations (100, 
50 and 10 μM) of T3 solution 
or T3-containing liposomes 
(Conv-LIPO, Stealth-LIPO, and 
Lf-Stealth-LIPO) at differ-
ent incubation time (24, 48 
and 72 hours). The value ob-
tained with treated cells was 
expressed as percentage of 
the value obtained whit con-
trol cells: untreated cells 
for T3 solution and cells 
treated with the empty formu-
lation for T3-containing li-
posomes. In FaO cells (Figure 
19) increasing concentrations 
of T3 (in solution or load-
ed liposomes) did not induce 
any cytotoxic effect since 
cell viability was statis-
tically similar to that ob-
served for control cells. By 
contrast, in HepG2 and SKHep 
cells incubation in the pres-
ence of the highest concen-
tration of drug solution led 
to an increased cell mortal-
ity that reached almost 70% 
after 72 hours (Figures 20.a 
and 21.a). Instead, T3-incor-
porated liposomes did not in-
duce loss of cell viability 
even at the highest concentra-
tion (100 μM) but we observed 
a significantly increased cell 
proliferation. In particular, 
in HepG2 cells (Figure 20b, 
20c, 20d) the highest prolif-
erative activity occurs at 72 
hours for all three formula-
tions, reaching greater val-
ues at lower concentrations.
A similar effect was also seen 
in SKHep cells (Figure 21b, 
21c, 21d) where, for Conv-
LIPO, Stealth-LIPO, and Lf-
Stealth-LIPO, it was ob-
served a significant increase 
(p <0.001) in cell viabili-
ty compared to control (cells 
treated with the respective 
empty formulations) after 48 
hours; this proliferative ef-
fect was maintained up to 72 
hours. In SKHep, as well as 
in HepG2 cells, the prolif-
erative activity was higher 
at lower concentrations (50 
and 10 μM). Proliferative ef-
fect of T3 on hepatoma cells 
is not surprising. Indeed, it 
has been hypothesized that 
the antitumoral effect of T3 
is not due to cell death, 
but T3, by interaction with 
its TR receptors, negative-
ly influences the carcinogen-
ic process through induction 
of a differentiation program 
of preneoplastic hepatocytes. 
According to this hypothesis, 
malignant hepatocyte return 
to a fully differentiated phe-
notype with loss of the fetal 
markers GSTP and gamma glu-
tamyl transpeptidase, and re-
acquisition of the activity 
of glucose 6-phosphatase and 
adenosine triphosphatase, two 
enzymes expressed in normal 
hepatocytes [11].
All together these findings 
emphasize that liposomes pro-
tect the cells against the 
cytotoxicity of high concen-
tration of T3, since the li-
posome delivery system slowly 
release the drug inside the 
cells and significantly induce 
a proliferative effect at low 
concentrations. At the same 
time, the employment of low-
er drug concentrations should 
allow to reduce the possible 
side effects on other target 
cells (e.g. heart).
5. Conclusions
In conclusion, this study 
provides useful information 
about the great potential of 
liposomes as suitable carrier 
for T3 delivery to hepatoma 
cells. Internalization stud-
ies performed using Lf-mod-
ified-liposomes labeled with 
the lipophilic marker Rho-
PE and loaded with the hy-
drophilic probe CF clearly 
demonstrated the effective in-
ternalization of both hydro-
philic and lypophilic mark-
ers. From our data, emerges 
that liposome delivery system 
may insure a specific and sus-
tained drug delivery, a re-
duced therapeutic dose and, 
in particular, should avoid 
deleterious side effects of T3 
treatment. Overall, our re-
sults showed that liposomes 
are good candidates as liver 
delivery system of T3 since 
cell viability tests per-
formed by using hepatoma cell 
lines demonstrated a very low 
toxicity of all three lypos-
ome formulations. 
Further studies are needed 
in order to analyze the ef-
fectiveness of this delivery 
system in in vivo models.
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Figure 16 In vitro cytotoxic effect of increasing concentrations of empty lipos-
ome formulations Conv-LIPO (a), Stealth-LIPO (b) and Lf-Stealth-LIPO (c) on FaO 
cells at different coincubation times (24, 48 and 72h). * p <0.05, ** p <0.01 
and *** p <0.001 in comparison with untreated cells (100% viability). Data rep-
resented the mean ± SD (n = 3).
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Figure 18 In vitro cytotoxic effect of increasing concentrations of empty li-
posome formulations Conv-LIPO (a), Stealth-LIPO (b) and Lf-Stealth-LIPO (c) 
on SKHep cells at different coincubation times (24, 48 and 72h). * p <0.05, ** 
p <0.01 and *** p <0.001 in comparison with untreated cells (100% viability). 
Data represented the mean ± SD (n = 3).
Figure 17 In vitro cytotoxic effect of increasing concentrations of empty li-
posome formulations Conv-LIPO (a), Stealth-LIPO (b) and Lf-Stealth-LIPO (c) 
on HepG2 cells at different coincubation times (24, 48 and 72h). * p <0.05, ** 
p <0.01 and *** p <0.001 in comparison with untreated cells (100% viability). 
Data represented the mean ± SD (n = 3).
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Figure 19 In vitro cytotoxicity assays: FaO cells incubated with different con-
centrations of T3 solution (a) or T3-containing liposomes (Conv-LIPO (b), 
Stealth-LIPO (c) and Lf-Stealth-LIPO (d)) at different incubation time (24, 48 
and 72 h). * p <0.05, ** p <0.01 and *** p <0.001 in comparison with control 
cells (100% viability):untreated cells for T3 solution and cells treated with 
the empty formulation for T3-containing liposomes Data represented the mean ± 
SD (n = 3).
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Figure 20 In vitro cytotoxicity assays: HepG2 cells incubated with different 
concentrations of T3 solution (a) or T3-containing liposomes (Conv-LIPO (b), 
Stealth-LIPO (c) and Lf-Stealth-LIPO (d)) at different incubation time (24, 48 
and 72 h). * p <0.05, ** p <0.01 and *** p <0.001 in comparison with control 
cells(100% viability):untreated cells for T3 solution and cells treated with 
the empty formulation for T3-containing liposomes Data represented the mean ± 
SD (n = 3).
0
20
40
60
80
100
120
140
160
180
 100µM 50µM 10µM
%
 
v
i
a
b
i
l
i
t
y
 
v
s
 
c
o
n
t
r
o
l
24h 48h 72h
0
20
40
60
80
100
120
140
160
180
 100µM 50µM 10µM
%
 
v
i
a
b
i
l
i
t
y
 
v
s
 
c
o
n
t
r
o
l
24h 48h 72h
A - T3 sol
B - Conv-LIPO T3
**
*
***
***
0
20
40
60
80
100
120
140
160
180
 100µM 50µM 10µM
%
 
v
i
a
b
i
l
i
t
y
 
v
s
 
C
o
n
t
r
o
l
24h 48h 72h
0
20
40
60
80
100
120
140
160
180
 100µM 50µM 10µM
%
 
v
i
a
b
i
l
i
t
y
 
v
s
 
c
o
n
t
r
o
l
24h 48h 72h
C - Stealth-LIPO T3
D - Lf-Stealth-LIPO T3
** **
** *
Liposomes for triiodothyronine delivery to hepatoma cells: 
development, characterization and in vitro studies
6564 PhD Program XXVII - Nanosized systems for efficient delivery of antitu-
moral and anti-inflammatory drugs.
Figure 21 In vitro cytotoxicity assays: SKHep cells incubated with different 
concentrations of T3 solution (a) or T3-containing liposomes (Conv-LIPO (b), 
Stealth-LIPO (c) and Lf-Stealth-LIPO (d)) at different incubation time (24, 48 
and 72 h). * p <0.05, ** p <0.01 and *** p <0.001 in comparison with control 
cells (100% viability):untreated cells for T3 solution and cells treated with 
the empty formulation for T3-containing liposomes Data represented the mean ± 
SD (n = 3).
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II. Nanosuspensions
2. Nanosuspensions plied only for drugs exhibit-
ing special features, such as 
solubility in specific organic 
solvents or molecular struc-
tures fitting in the cyclodex-
trin rings.
For many years, micronization 
has also been used as gener-
al and simple approach to in-
crease dissolution velocity 
of poorly water-soluble com-
pounds [10]. In the microni-
zation process (jet milling or 
wet milling) coarse drug pow-
ders are disintegrated in ul-
trafine powders characterized 
by drug crystal average diam-
eters typically in the range 
of 2-5 µm. The reduction of 
crystal drug diameter enlarg-
es the surface area thus in-
creasing the dissolution ve-
locity, as described by the 
Nerst-Brunner/Noyes-Whitney 
equations [11].
However, for drug with very 
low saturation solubility, 
micronization is not suffi-
cient to achieve an adequate 
bioavailability. Consequent-
ly, the next step was the pro-
duction of nanocrystals.
Nanocrystals can be defined as 
nanoparticles of pure drug 
without any matrix material 
1. Introduction
The number of poorly wa-
ter-soluble molecules with 
potential therapeutic activ-
ity has progressively in-
creased in the last years. As 
reported in literature, more 
than 40% of the new chemi-
cal entities in the pipeline 
and about 70% of drug coming 
directly from discovery pro-
grams are poorly soluble [1]. 
These molecules are very of-
ten characterized by a highly 
variable bioavailability, in 
particular too low oral bio-
availability and erratic ab-
sorption profiles due to their 
low dissolution velocity and 
saturation solubility.
Different strategies including 
the use of salts, co-solvents 
[2], solubilizing agents [3], 
co-crystal formulations [4], 
pH adjustment [5], solid dis-
persions [6], lipid based 
formulations [7] (e.g. lipos-
omes and microemulsions) [8], 
incorporation into inclu-
sion complexing agents (cy-
clodextrins) [9], have been 
used to enhance drug solubil-
ity. However, most of these 
strategies have limited suc-
cess because they can be ap-
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with an average diameter be-
low 1 μm (typically in the 
range of 200-500 nm) [12,13]. 
Nanocrystals can be prepared 
in both water and non-water 
media as colloidal suspension 
(referred to as nanosuspen-
sions) stabilized using sur-
factants (ionic or non-ionic) 
or polymers.
Compared to micronized pow-
ders, the reduction of the 
drug crystal average diameter 
below 1 μm not only increas-
es the particle surface area 
but also decreases the diffu-
sion layer thickness, as de-
scribed by the Prandtl equa-
tion, further increasing the 
dissolution velocity [14]. In 
addition, as described by the 
Freundlich–Ostwald equation, 
nanocrystals are characterize 
by an increased saturation 
solubility not observed with 
micronized crystals [15].
Nanocrystals can be prepared 
using two different approach-
es: the bottom up and the top 
down technologies or a combi-
nation of two (Figure 1) [16]. 
In the bottom up technology, 
the low water soluble drugs 
are (molecularly) dissolved 
in a solvent and then pre-
cipitated in different ways as 
nanocrystals in a surfactant 
solution [17]. The top down 
technology is based on parti-
cle disintegration techniques 
including beads wet milling 
[18–21].
The drug absorption through 
the gastro intestinal tract 
(GIT) is basically character-
ized by two distinct steps: 
the drug dissolution into the 
GIT fluids and the drug trans-
port across the GI membranes. 
Normally, in oral administra-
tion, the dissolution step 
is the rate limiting the ab-
sorption process. Poorly wa-
ter-soluble drugs, belonging 
to class II and IV of the bi-
opharmaceutical classification 
system (BCS) which absorption 
is limited by the low dissolu-
tion velocity, are character-
ized by no reproducible oral 
absorption, low bioavailabil-
ity and absorption variation 
in the fed or fast state.
One of the first article de-
scribing the potential use of 
nanosuspension for oral ad-
ministration was published 
by Merisko-Liversidge et al. 
[22]. The authors demonstrat-
ed the ability of nanosus-
pensions to improve the bi-
oavailability of the poorly 
water soluble gonadotropin 
inhibitor Danazol in fasted 
male beagle dogs. At a dose of 
200 mg danazol nanocrystals 
with a mean diameter of about 
169 nm showed an absolute bi-
oavailability of 82.3%, 16 
times greater than that ob-
tained using danazol marketed 
microsuspension (5.2%). Fur-
thermore, the Cmax (maximum 
plasma concentration) was in-
creased by 15 times and the 
Tmax (time to maximum plasma 
concentration) was reduced. 
Ever since, the ability of 
nanocrystals to increase the 
dissolution velocity and sat-
uration solubility in vitro 
[23] and the oral biovaila-
bility in vivo has been ex-
tensively demonstrated in dif-
ferent animal models [24–26].
Formulation of poorly solu-
ble drugs in nanosuspension 
has already achieved resound-
ing success as also confirmed 
by the five oral and one paren-
teral medicinal products al-
ready on the market [27].
Interesting, nanocrystals 
dispersed in orally disin-
tegrating tablets or polymer 
orodispersible films have been 
also studied for buccal ad-
ministration of several drugs 
such as pyroxicam, querce-
tin and herpetrione as model 
drugs [28–30]. Overall, out-
comes from these studies in-
dicated a great amelioration 
of the dissolution veloci-
ty in vitro when the drugs 
are formulated in nanocrystal 
form.
Furthermore, intravenous in-
jection of nanosuspension 
formulations has been exten-
sively studied and several 
articles and reviews concern-
ing this route of adminis-
tration have been published 
[31–34]. Basically, intra-
venous injected nanocrystals 
or immediatly dissolve in the 
blood (very small nanocrystal 
or drug having an high in-
trinsic solubility), or slow-
ly dissolve and accumulate in 
liver, lungs and spleen af-
ter recognition by the mon-
onuclear phagocyte sys-
tem (larger nanocrystals of 
drugs having very low water 
solubility).
Besides they have been espe-
cially studied for oral and 
parenteral administration, 
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Figure 1. Schematic representation of the main nanocrystals production meth-
ods. Adapted from Ref. [16].
nanocrystals have showed a 
great potential also for top-
ical delivery through alter-
native routes such as the 
dermal, pulmonary and ocu-
lar route, which have not 
been intensely reviewed in 
literature.
For these reasons, in this 
thesis the use of nanocrys-
tals for enhance dermal bi-
oavailability of poorly sol-
uble drugs was investigated.
1.1. Methods of production
Fundamentally, there are two 
approaches to produce drug 
nanocrystals the top down and 
the bottom up technologies as 
well as a combination thereof 
(Figure 1).
 
1.1.1. Top down technologies
Top down process consists in 
reducing large drug crystal 
particles (micro range) into 
smaller crystals (nanometer 
range) by using different wet 
milling techniques such as 
media milling, microfluidiza-
tion and high pressure homog-
enization. These technologies 
do not make use of aggres-
sive solvents and, thus, are 
considered suitable for for-
mulations as nanocrystals of 
all insoluble drugs including 
“brick dust drugs” (drugs in-
soluble in any solvent) (Fig-
ure 1).
Wet ball media milling
In the first 1990s, for the 
first time, Gary Liversidge 
and his coworkers of the com-
pany Sterling Drug Inc./East-
man Kodak, adapted a wet me-
dia-based milling technique 
used in the photographic in-
dustry to reduce the particle 
size of poorly water-soluble 
drugs [35]. Few years lat-
er, this milling technology 
was registered with the trade 
name NanoCrystal® by the com-
pany Elan Pharma Internation-
al Ltd. Since then, wet ball 
media milling (WBM, known as 
pearl milling or bead mill-
ing) was developed demon-
strating to be a very effec-
tive top-down process and, 
hence, becoming quickly the 
referential technology in na-
nosuspension pharmaceutical 
industry [36–38]. At pres-
ent, WBM technology is repre-
sented in the market with five 
products (Rapamune® (Wyeth), 
Emend® (Merck), TriCor® (Ab-
bott Laboratories), Triglide® 
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(Skye Pharma) and Megace ES® 
(Bristol-Myers Squibb) [39]. 
The milling procedure is very 
simple, achievable in almost 
all laboratories and univer-
sally applicable to most drug 
candidates or, more in gen-
eral, to all solid materials 
[21]. On the whole, WBM tech-
nology can be divided in two 
different energetic processes: 
a low energy and a high ener-
gy wet ball milling.
In the former method, a drug 
coarse aqueous suspension 
containing stabilizers (pol-
ymers and/or surfactants) is 
mixed with the media mill-
ing (beads) in a jar or in 
a becker by using a stirrer 
at very high speeds (becker) 
or a roller plate or a mix-
er (jar). Continuous strong 
collisions between the mi-
cron-sized drug particles and 
the beads lead to a combi-
nation of cleavage, abra-
sion and fractures and con-
sequently to a size reduction 
of the crystals down to the 
nanometer size range [40]. 
Surfactants or polymers are 
usually added to avoid aggre-
gation phenomena of the newly 
formed nanocrystals as well 
as to minimize crystal growth 
on storage [41,42]. Unfortu-
nately, although this tech-
nique produces very small and 
homogeneous nanometer-parti-
cles, the low energy supplied 
normally leads to very long 
milling times that can even 
reach several days [35,43]. 
On the contrary, the pat-
ented NanoCrystal® technolo-
gy is based on a high energy 
WBM performed using specif-
ic equipment [44] . The high-
er power density supplied to 
the drug suspension allows to 
reduce significantly the pro-
duction time needed to obtain 
nanosuspensions (30–120 min) 
of the desired size [45]. For 
this reason, today, the high 
energy WBM is considered the 
procedure of choice in the 
production of nanosuspen-
sions. An important drawback 
of this technique was high-
lighted: nanosuspension con-
tamination phenomena caused 
by abrasion of both milling 
media or parts of the equip-
ment material, especially 
when glass or zirconium beads 
were used [46,47]. However, 
this problem has been over-
come when new, more deform-
able beads made of zirconium 
alloy, stabilized with yttri-
um or polystyrene, were in-
troduced [38,42]. Nowadays, 
equipments capable of produc-
ing small quantities of na-
nosuspensions or different 
types of nanosuspensions at 
the same time are available, 
thus, making this WBM tech-
nology a very scalable method 
as well as the most versatile 
top down process [48,49]. In-
deed, all poor soluble drugs 
can be milled and, conse-
quently, reduced in size by 
using this technique [50].
High pressure homogenization
High pressure homogenization 
(HPH) is considered the sec-
ond most important process to 
produce drug nanocrystals. 
When the first nanosuspensions 
were formulated by using this 
technique, various types of 
homogenizers (both at high 
or low pressure) had already 
been employed in food field, 
while pharmaceutical industry 
employed this technique for 
the first time in 1990 in the 
preparation of liposomes and 
different emulsions [51,52].
Basically, there are three 
main approaches to produce 
nanosuspensions by HPH: in-
soluble drug delivery tech-
nology (IDD®) also referred 
as Microfluidizer technology 
(Microfluidizer®, Microfluidics 
Inc.), the piston-gap homoge-
nization in water or, alter-
natively,  in water-reduced/
non-aqueous media [53,54].
Historically, the first HPH 
patented technique is the 
IDD® technology, developed 
in 1992 by the Research Tri-
angle Pharmaceuticals compa-
ny (now SkyePharma, Canada). 
IDD® is based on the use of a 
jet stream homogenizer, known 
as microfluidizer. In the mi-
crofludizer, the drug coarse 
suspension moves at high 
pression and speed through 
two different homogenization 
chambers. In the first cham-
ber (the so called “Z” cham-
ber), the coarse particles 
change quickly their flow di-
rection randomly, therefore, 
colliding each other. On the 
”Y” chamber (the second one), 
suspension flow is divided in 
two leading to a frontal col-
lision of the new two gener-
ated flows. In both chambers, 
particle collision, shear and 
cavitation forces lead to the 
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desired particle size reduc-
tion. Unfortunately, this 
technique requires too long 
preparation times due to the 
high number of passes through 
the homogenizer. Moreover, it 
generally leads to a modest 
size reduction with hard drug 
nanosuspensions often con-
taining a relatively large 
fraction of microparticles, 
and a consequent drop of the 
typical nanosuspensions ad-
vantages. However, Triglide® 
(fenofibrate) is an example of 
a marketed formulation pro-
duced using the microfluidizer. 
In 1994, an alternative tech-
nology based on piston gap 
high pressure homogeniza-
tion was developed by Müller 
and his team to produce small 
and homogeneous drug nano-
crystals. Due to the cubic 
form of the obtained crys-
tals (in contrast to spher-
ical amorphous drug nanopar-
ticles produced by IDD®), the 
trade name of this new meth-
od was DissoCubes®  [55]. As 
for IDD® technology, in 1999 
Dissocubes® was acquired by 
SkyePharma. In this technolo-
gy, the coarse drug suspend-
ed in an aqueous surfactant 
solution is pushed several 
times by a piston under high 
pressure (from 1500-2000 bar 
up to 4000 bar) through a tiny 
gap (5–20 μm). The consequent 
high flow speed of the coarse 
suspension and the dras-
tic reduction in the diame-
ter from the cylindrical de-
posit (about 3 cm) to the tiny 
gap lead to an increased dy-
namic pressure. At the same 
time, static pressure falls 
below the vapor pressure of 
the external phase (water) 
compensating the increased 
dynamic pressure in the sys-
tem: the water boils and the 
newly formed bubbles collapse 
quickly when the suspension 
escapes from the gap. The 
turbulence caused by these 
phenomena (cavitation) gener-
ates drug macrocrystal frag-
mentation in nanocrystals. 
In general, the pressure in-
side the homogenizer gradual-
ly increases from 10% to 100% 
as pre-milling. Normally, to 
prevent a possible obstruc-
tion of the tight homogeniz-
er gap, the coarse suspension 
is previously submitted to a 
de-agglomeration phase using 
high-speed stirrers. It must 
be underlined that here, cav-
itation forces play a funda-
mental role in drug crystal 
reduction but other factors 
are also involved, i.e. shear 
forces, and crystal against 
crystal and crystal against 
homogenizer wall collisions 
[56]. Moreover, several ho-
mogenization cycles are needed 
to obtain the desired crystal 
size using the Microfluidizer 
technique. Three main factors 
are considered to affect drug 
nanocrystals size obtained 
by the HPH technology: type 
and power density of the ho-
mogenizer, number of homoge-
nization cycles, drug hard-
ness and size of the starting 
material.
While coarse suspension moves 
through the homogenizer gap 
under pressure, particles 
start to crash nearby crumbly 
points becoming (after each 
cycle) smaller, more homoge-
neous, compact and, obvious-
ly, also more difficult to be 
further reduced. Thus, both 
the choice of the homogeniz-
er equipment (the greater the 
equipment power density the 
easier the reduction process 
of crystal dimension) and the 
number of cycles to perform 
(more cycles mean more prob-
ability to break “survived 
crystals” at the following 
cycle) appears crucial fac-
tors. Furthermore, the softer 
the drug the lower is the sys-
tem energy required to reduce 
crystals size and vice versa. 
Drug hardness can also affect 
another important aspect in 
any production process: ero-
sion phenomena of the inter-
nal surfaces of the equipment 
and subsequent steel contam-
ination of the final product. 
Normally, high pressure ho-
mogenization is less inclined 
in generating process impu-
rities as a consequence of 
abrasion and wearing of the 
equipment if compared to WBM 
(below 1 ppm after 20 cycles 
at 1500 bar) [57]. However, 
after a certain time of usage 
or when extremely hard mate-
rial is processed, the tip 
of the homogenization valve 
can show some signs of wear 
due to cavitation and parti-
cle impact, so the default 
smooth surface will appear 
scratched. 
In 1999, starting from Dis-
socubes® technology, the Ger-
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man company PharmaSol GmbH 
(now Abbott Laboratories) de-
veloped an alternative pis-
ton gap homogenization pro-
cess registered with the 
trade name of Nanopure® tech-
nology (pure nanocrystals) 
[58]. This technology uses, 
as primary dispersion me-
dium, non-aqueous liquids, 
oils, liquid and solid (melt-
ed) PEG, or water reduced me-
dia (glycerol, water, ethanol 
or water mixtures). As high-
lighted above, the first pat-
ent of DissoCubes® is based on 
the dominating role of cavi-
tation in the homogenization 
process. In contrast to wa-
ter, oils and oily fatty acids 
have a very low vapour pres-
sure at room temperature, so 
cavitation takes place par-
tially or not at all. There-
fore, when water shows cav-
itation, the oil will not. 
Even without cavitation, the 
size reduction is sufficient 
because of the shear forces, 
particle collisions and tur-
bulences. Nanopure® technolo-
gy is especially suitable for 
the formulation of oral dos-
age forms. Production of drug 
nanocrystals in a mixture of 
water and water-miscible liq-
uids has some process advan-
tages, for example in case 
of spray-drying or lyophili-
sation. In addition, it al-
lows the production of iso-
tonic drug nanosuspensions 
for i.v. administration in a 
one-step production process 
(homogenization in an isoton-
ic glycerol–water mixture). 
In conclusion, high pressure 
homogenization represents an 
efficient method to produce 
nanocrystals, especially for 
relatively soft drugs, al-
though the obtained nanosus-
pension seems to be less ho-
mogeneous if compared with 
that obtained with the wet 
ball milling process. Moreo-
ver, HPH is a scalable method 
(used in pharmaceutical, food 
and cosmetics fields)  and ap-
plicable both in laborato-
ry and industrial production 
[20,59].
On the contrary, the choice 
of the stabilizer seems to 
be a less determining fac-
tor since, in nanosuspension 
technology, the stabiliz-
ers do not affect either crys-
tal reduction or crystal form 
but only play a role in pre-
venting aggregation phenome-
na of the new obtained na-
nocrystals, i.e. in long-term 
stability. 
1.1.2. Bottom-up technologies
In the bottom-up technology, 
also termed as nanoprecipita-
tion, the process starts from 
a supersaturated drug solu-
tion, where the molecules 
grow and precipitate in the 
form of nanocrystals. Pre-
cipitation can be induced by 
processes that further in-
crease the supersaturation, 
such as reduction of tempera-
ture, evaporation of the sol-
vent or by mixing it with an 
antisolvent (Figure 1). At a 
higher extent of supersatu-
ration, the nucleation rate 
increases, and, then, the 
crystal size decreases. Cru-
cial in this process is it 
to control the structure of 
the particles (amorphous ver-
sus crystalline) and to avoid 
growth of the crystals to the 
µm size range. The first tra-
ditional precipitation meth-
od used to obtain drug na-
nocrystals was the so-called 
Hydrosol technique invented 
by List and Sucker in 1988 
[60]. In this technique, also 
called liquid solvent-anti-
solvent (LAS) precipitation, 
the drug is first solubilized 
in a suitable solvent, pref-
erably water miscible (e.g. 
acetone, ethanol, methanol, 
isopropanol (IPA), N-meth-
ylpyrrolidone (NMP)) and then 
mixed with an antisolvent (wa-
ter, in most of the cases), 
which must be miscible with 
the solvent phase. Mixing of 
the organic solution and the 
anti-solvent should be per-
formed rapidly to guarantee a 
fast nucleation and, thereby, 
small particles. To stabilize 
the nanocrystals, a stabiliz-
ing agent can be dissolved in 
the aqueous phase. Hereafter, 
the solvents can be removed 
by evaporation or lyophili-
zation to obtain a dry na-
nocrystalline drug product. 
The use of this technique for 
drug nanocrystal preparation 
was reported in several re-
search studies [61–64].
In order to obtain nanocrys-
tals with a smaller particle 
size or narrower particle size 
distribution (PSD), modified 
LAS precipitation methods are 
reported in literature. The 
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lower particle size obtained 
by these modified methods is a 
result of either faster mix-
ing to affect the nucleation 
stage or by blocking parti-
cle growth. Additional exter-
nal energy, such as ultra-
sounds, has been demonstrated 
to enhance a rapid mixing 
[65]. However, sonoprecipita-
tion has been employed only 
for very few drugs [66–71]. 
Alternatively, precipita-
tion can be carried out in 
combination with centrifuga-
tion (High gravity antisol-
vent precipitation) [72–74]. 
Another modified solvent-an-
tisolvent precipitation meth-
od is the evaporative precip-
itation into aqueous solution 
(EPAS). In the EPAS process, 
the drug precipitates due to 
evaporation of the organ-
ic solvent close or above the 
boiling point [75–77].
Supercritical fluid (SCF) 
technologies have been pro-
posed as alternatives to liq-
uid solvent-antisolvent pro-
cesses. The most relevant SCF 
methods include rapid expan-
sion of supercritical solu-
tions (RESS) and supercrit-
ical antisolvent process 
(SAS). The RESS technique was 
described for the first time 
in 1999 by Pace et al. in the 
preparation of drug nanocrys-
tals [78]. In this process, 
the supercritical fluid, such 
as supercritical carbon diox-
ide, acts as a solvent. The 
drug solution rapidly expand 
across an orifice or a cap-
illary nozzle into ambient 
air. The fast pressure re-
duction in the expansion is 
characterized by high degrees 
of supersaturation, resulting 
in the homogeneous nucleation 
and, thereby, the formation 
of well-dispersed particles. 
A modified method called rap-
id expansion of supercriti-
cal solution with solid co-
solvent (RESS–SC) was used 
for drugs with low solubili-
ty in the SCF [79,80]. In ad-
dition, further modifications 
of the RESS technique led to 
processes called, respective-
ly, rapid expansion of a su-
percritical solution into a 
liquid solvent (RESOLV) and 
rapid expansion from super-
critical to aqueous solution 
(RESAS). RESOLV and RESAS 
technologies were later used 
for preparing nanoparticles 
of various other compounds as 
well [58,81–83].
In contrast, in the SAS pro-
cess the supercritical flu-
id acts as an anti-solvent. 
An organic drug solution is 
mixed with the supercritical 
antisolvent leading to a pre-
cipitation of nanometer-sized 
drug particles, which are 
collected in various ways. A 
solution of the drug in an 
organic solvent is saturat-
ed with supercritical fluid, 
thus, decreasing the solubil-
ity of the drug in the solvent 
and causing consequently the 
drug precipitation. Several 
examples of using SAS meth-
od for nanosized drug parti-
cle production are shown in 
the literature [53,84] . De-
pending on process condi-
tions and mixing types, var-
ious process variants exist: 
gas antisolvent process (GAS) 
[85], solution-enhanced dis-
persion by supercritical flu-
ids (SEDS) [86], aerosol su-
percritical extraction system 
(ASES) [85,87] and SAS with 
enhanced mass transfer (SAS–
EM)[88,89].
More recently, bottom-up 
techniques, such as con-
trolled crystallization dur-
ing freeze drying (CCDF) [90], 
spray-freezing into liquid 
[91] or nanoprecipitation in 
microfluidic reactors [92,93], 
were developed to prepare 
drug nanocrystals. In CCDF, 
a drug solution in an organ-
ic solvent is mixed with an 
aqueous solution of a cryo-
protectant and, then, immedi-
ately frozen and lyophilized. 
Freeze-drying is performed at 
a relatively high temperature 
(above the glass transition 
temperature of the maximally 
freeze-concentrated fraction) 
to allow the drug and matrix 
to crystallize. Faster freez-
ing rate and lower water con-
tent induce higher nucleation 
rate, which reduces the size 
of the solvent crystals and, 
thereby, the interstitial 
spaces among them. Small-
er interstitial spaces limit 
the growth of the drug crys-
tals. However, this method is 
only suitable for drugs with 
low glass transition temper-
ature (Tg). To scale up this 
method for large scale pro-
duction, the mixing step was 
modified by using a 3-way noz-
zle (for solvent, antisolvent 
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and atomizing air) [94]. The 
fine droplets of solvent and 
antisolvent, generated by at-
omizing air, mix one another 
as soon as they leave the noz-
zle, and the mixture directly 
enter into the liquid nitro-
gen for freezing. 
Spray-freezing into liquid 
(SFL), which consists of sim-
ilar process steps as CCDF, 
was first proposed by Hu et 
al [91]. The drug can be dis-
solved either in a mixture of 
aqueous/organic solvent or in 
pure organic solvent, with or 
without stabilizer, and then 
sprayed into liquid nitrogen 
for immediate precipitation 
of amorphous particles in a 
nanometer size [95]. The SFL 
process has several advantag-
es in comparison with other 
precipitation methods that 
use spray technique, i.e. 
EPAS. Indeed, the SFL process 
leads to highly porous, amor-
phous and smaller size nano-
structured particles in the 
form of solid solution. On 
the contrary, the EPAS pro-
cess produces particles rel-
atively larger and, further-
more, the miscibility of the 
polymer and the drug is low. 
This results in higher disso-
lution rates of the particles 
prepared by SFL if compared 
to the EPAS process [54].
Bottom-up processes are low 
energy processes, require 
simple instruments, are less 
expensive and can be operated 
at a low temperature, making 
them particularly suitable 
for thermolabile drugs. How-
ever, a basic disadvantage of 
many precipitation processes 
is the use of organic sol-
vents, which need to be re-
moved, leading to high cost 
of production. Particularly, 
in case of low soluble drug 
in water and organic solvent, 
large solvent volumes are re-
quired. Moreover, advanced 
techniques like processing 
with supercritical fluid are 
more expensive. Hence, in the 
pharmaceutical industry, the 
bottom up processes are not 
employed for the production 
of marketed drugs [17].
1.1.3. Combination technolo-
gies
The combination of a pre-treat-
ment step with following high 
energy step have been intro-
duced to overcome limitations 
sists of a family of various 
combination processes, where 
a pre-treatment step is fol-
lowed by a high pressure ho-
mogenization (HPH) step to 
accelerate nanocrystal pro-
duction and/or obtain small 
nanocrystal size below 100 
nm. Several processes, such 
as the CT (combination tech-
nology) process (pearl mill-
ing followed by high pressure 
homogenization)[97], the H 69 
technology (cavi-precipita-
tion followed by high pressure 
homogenization) [98,99], the 
H 96 technology (freeze-dry-
ing followed by high pressure 
homogenization)[100] and the 
H 42 technology (spray-drying 
followed by high pressure ho-
mogenization)[101] belong to 
this family. Literature pro-
vides many examples where 
combinational technologies 
have produced stabilized na-
nocrystals [93,102–105].
Recently, a novel tri-com-
bination technology, the so 
called “Precipitation-ly-
ophilization-homogenization 
(PLH) method” has been pro-
posed for preparing nano-
crystals [106]. Here, the 
solvent-antisolvent precip-
and to improve the particle 
size reduction effectiveness 
of the single “bottom-up” or 
“top-down” strategies (Figure 
1). The patent combination 
technologies are, for exam-
ple, Nanoedge® and smartCrys-
tal® technologies.
The Nanoedge® technology by 
Baxter consists of a bot-
tom-up step (micro-precipita-
tion) followed by a top-down 
step (high-pressure homoge-
nization). The drug is dis-
solved, e.g. in a water-mis-
cible, non-aqueous media and 
precipitates in form of a sus-
pension consisting of fragile 
drug particles This suspen-
sion is then further pro-
cessed to nanosuspension by 
means of high-pressure ho-
mogenization. In the presence 
of high energy, the unstable 
form of the drug particles is 
converted to a stable crys-
talline particle [96].
On the contrary, SmartCrys-
tal® technology is considered 
as the second generation of 
drug nanocrystals and it is 
owned by Abbott and market-
ed by its drug delivery com-
pany Soliqs in Ludwigshafen/
Germany. This approach con-
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Figure 2 Schematic representation of skin layers.
itation process is used to 
reduce the starting parti-
cle size prior to homogeniza-
tion. Then, a lyophilization 
step follows, thus, allowing 
the solvent to be completely 
removed and providing porous 
and friable drug particles. 
Finally, the application of 
high pressure homogenization 
may facilitate the reduction 
of drug crystals to the nano-
meter size range.
In addition to this combi-
national methods, ultrasonic 
sound was used as pre-treat-
ment step followed by high 
pressure homogenization [107] 
as well as a high energy step 
to reduce the particle size 
after precipitation [108]. 
1.2. Dermal delivery
The skin represents an im-
portant site for non-inva-
sive and painless delivery of 
therapeutic agents with pos-
sibility to control their re-
lease and to avoid the first-
pass metabolism [109]. After 
dermal absorption drugs can 
reach different target sites 
and exert topical, regional, 
or systemic effects. For these 
reasons, delivery of drugs 
through the skin has been con-
sidered an attractive as well 
as a challenging research area 
[110,111]. The primary chal-
lenge is overcoming the unu-
sually impermeability of the 
skin barrier. The skin (Fig-
ure 2) is a complex structure 
that protects the human body 
preventing invasion of path-
ogens and fending off chemi-
cal and physical assaults and 
controls essential processes 
like thermal regulation. It 
is made up of several anatom-
ically distinct layers, name-
ly the stratum corneum (SC), 
the viable epidermis and the 
dermis [112]. The physical 
barrier is mainly localized 
in the SC and consists of 
protein-enriched dead cells 
(corneocytes with cornified 
envelope and cytoskeletal el-
ements, as well as corneodes-
mosomes) and lipid-enriched 
intercellular domains which 
are organized as multiple li-
pid bilayers (lamellar sheets 
composed of approximately 
equimolar concentrations of 
free fatty acids, cholester-
ol, and long chain ceramides) 
[113]. The nucleated epider-
mis also contributes to the 
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Figure 3. Proposed mechanism of increased dermal penetration of drug actives 
formulated as nanocrystals via (A) increased penetration into skin surface (ep-
idermis) and (B) localization of nanocrystals in the hair follicles. Adapted 
from Ref. [120].
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barrier through tight, gap 
and adherent junctions, as 
well as through desmosomes 
and cytoskeletal elements. 
Therefore, the skin barrier 
function is not only depend-
ent on one single component 
but on its total architec-
ture [114]. Appendages such 
as sweat glands, piloseba-
ceous units, and hair folli-
cles are structures originate 
either from the dermis or the 
subcutaneous fat tissue which 
penetrate the skin thus form-
ing important discontinuities 
in this compact structure 
[115]. Drugs applied to the 
skin surface enter the skin 
by a passive diffusion process 
through two pathways such as 
the transappendegeal and the 
transepidermal routes (Figure 
3). The skin appendages pres-
ent an alternative pathway 
for drug delivery into the 
skin, raising the possibility 
of avoiding the difficulty of 
delivering drug through the 
SC. This route was tradition-
ally considered of minor im-
portance because of the rela-
tively small area, but recent 
results on follicular pene-
tration have emphasize that 
the hair follicles pathway 
may plays a major role as skin 
penetration pathway and res-
ervoir of topically applied 
molecules. Moreover, the 
hair follicles and sebaceous 
glands are associated with 
various dermatological dis-
orders such as acne, alope-
cia, and several skin tumors 
[115]. Through the epidermis, 
there are two different routes 
by which a molecule can cross 
this barrier: the transcellu-
lar, across the corneocytes 
and the intercellular across 
the lipid domains between 
the corneocytes. Although it 
is generally accepted that 
the intercellular route pro-
vides the principal pathway 
for the permeation of drugs, 
also this route is severely 
limited by the inability of 
the large majority of drugs 
to cross the skin at thera-
peutic rates due to the great 
barrier imposed by the out-
er SC layer [109,110,114]. To 
increase skin permeability, a 
number of different approach-
es has been studied, ranging 
from chemical enhancers to 
soft matter nanocarriers such 
as liposomes, which oppor-
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tunely formulated might have 
the potential to meet the de-
mands [116,117]. Among the 
various strategy for enhanc-
ing dermal application, nano-
crystals can be considered a 
rather new but highly inter-
esting approach [13,118]. De-
spite several nanosuspension 
products have become very 
fast available in the last 10 
years, with most of them in-
tended for oral administra-
tion, only few research has 
been dedicated to the study 
of skin permeation and accu-
mulation of drugs formulat-
ed as nanosuspension. Howev-
er, the few published results 
clearly indicate that this 
technology could be very ef-
fective for improving dermal 
bioavailability of actives 
with both poor and more re-
cently, medium solubility. 
Indeed, besides the increased 
saturation solubility and 
dissolution rate, nanocrys-
tals also exhibit the proper-
ty of increased adhesiveness 
to the skin thus facilitating 
the dermal delivery [12,13]. 
The interest towards this 
technology for dermal appli-
cation has been raising since 
2007, when the first anti-ag-
ing and skin-protective cos-
metic products based on nano-
suspensions of poorly soluble 
antioxidants rutin and hes-
peridin have been introduced 
to the market [119]. Rutin 
nanocrystals were produced by 
a combination process of low 
energy pearl milling followed 
by high pressure homogeni-
zation. When applied on the 
skin of human volunteers, a 
nanosuspension with 5% rutin 
as non-dissolved nanocrystals 
showed a 500-fold higher an-
tioxidant activity compared 
with a 5% solution of a wa-
ter soluble rutin-glycoside 
derivative. Due to the high-
er solubility of active rutin 
as a nanocrystal, there is an 
increased concentration gra-
dient between dermal formula-
tion and skin, which leads to 
a higher penetration when com-
pared to large drug crystals. 
Rutin penetrated into the 
skin is immediately replaced 
by fast dissolving molecules 
from the nanocrystals. More-
over, compared to the hydro-
philic rutin-glucoside, the 
original lipophilic molecule 
rutin can better penetrate 
into the skin where it is be-
lieved to have a higher af-
finity to the sites of action 
than the synthetically modi-
fied derivative [12,119]. As a 
consequence of these positive 
outcomes, several research 
focused on nanosuspensions 
of antioxidant molecules have 
been reported in literature 
since 2007 [120–123]. First, 
Mishra et al. produced na-
nocrystals of hesperetin, 
the aglycone of hesperidin, 
which has not only antioxida-
tive but also anti-inflammato-
ry properties and, therefore, 
is thought to be a very ef-
fective anti-aging compound. 
As these authors state, there 
is no difference in the proce-
dure for producing nanocrys-
tals for oral, intravenous or 
dermal application. The only 
difference in the formulations 
is the choice of the stabi-
lizers. Hence, in this study 
nanosuspensions of hesperetin 
were produced by high-pres-
sure homogenization employ-
ing four different stabiliz-
ers suitable for dermal use 
such as Poloxamer 188, Inutec 
SP1, Tween 80 and Plantacare 
2000, possessing different 
mechanisms of stabilization. 
Interestingly, as predicted 
from the zeta potential meas-
urements, Inutec and Plan-
tacare stabilized nanosus-
pensions were stable with no 
change in mean diameter size. 
Slight increases in size were 
found for Poloxamer and Tween 
stabilized nanosuspensions, 
which is not considered to 
impair their use in dermal 
formulations [121].
In 2011, Kobierski et al chose 
the anti-oxidant resveratrol 
as an ideal candidate to be 
used as nanocrystal in dermal 
cosmetic formulations such 
as creams, lotions and gels. 
Since preservation is essen-
tial for dermal formulations, 
resveratrol nanosuspensions 
were produced by a high pres-
sure homogenization process 
and the effects of preserva-
tives on physical stability 
were monitored as a function 
of cycle numbers [122]. The 
same year, Mitri et al pre-
pared a lutein nanosuspension 
by means of high pressure ho-
mogenization to enhance dis-
solution velocity and satu-
ration solubility, which are 
major factors determining 
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oral bioavailability and pen-
etration into the skin [123]. 
Lutein is a well-known anti-
oxidant and anti-free radical 
used in cosmetic, nutraceuti-
cal industry with potential 
application in pharmaceu-
tics as supportive antioxi-
dant. The main results from 
this study indicated that lu-
tein nanocrystals significant-
ly increased drug satura-
tion solubility (26.3 fold) 
as well as permeation through 
cellulose nitrate membranes 
(14 fold), compared to coarse 
powder. Moreover, no permea-
tion through pig ear skin oc-
curred, which supports the 
fact that lutein rather pene-
trates into the skin and re-
mains there where it should 
act as antioxidant [123].
A solid in oil nanosuspension 
of diclofenac sodium was the 
first pharmaceutical formula-
tions in which nanosuspension 
technology was applied to top-
ical application of a poor-
ly soluble therapeutic agent 
[124]. In this study, Piao et 
al successfully dispersed di-
clofenac sodium into isopro-
pylmiristate (oil phase) as 
a nanosized suspension via 
complex formation with su-
crose ester surfactant. The 
drug flux across the Yucatan 
micropig skin model was in-
creased up to approximately 4 
fold compared with a coarse 
oil suspension used as con-
trol. In a more recent paper, 
nanosuspension gel formula-
tions were studied as suita-
ble formulation approach for 
improving the skin permeabil-
ity of a poorly soluble mol-
ecule such as ibuprofen, a 
non-steroidal anti-inflammato-
ry drug used for the treatment 
of acute and chronic arthrit-
ic conditions [125]. Since 
the ibuprofen oral adminis-
tration can cause gastric mu-
cosal damage which may result 
in ulceration, its topical 
delivery can overcomes many 
side effects such as gastric 
complications. In this study, 
tocopherylpolyethyleneglycol 
1000 succinate (TPGS) and hy-
droxylpropylmethylcellulose 
(HPMC) were used as the basic 
components in nanoparticle 
ibuprofen formulations. TPGS 
was used to enhance the drug 
permeability (tested in both 
porcine and human skin) and 
to stabilize the system by hy-
drophobic interactions, while 
HPMC was used as a steric sta-
bilizer to inhibit crystal 
growth of the drug in the for-
mulation. Results of experi-
ments clearly indicated that 
the overall skin permeation 
enhancement process strongly 
depended on the solubilizer 
as well the particle size of 
the drug crystals. These fac-
tors resulted in higher drug 
release due to the formation 
of supersaturated solution 
around the crystals and thus 
a high concentration gradi-
ent was produced between the 
drug crystals and skin sur-
face. Authors conclude that a 
number of factors including 
the particle size of the drug 
crystals, surface properties 
of the carrier, interaction 
of drug molecule with the sta-
bilizer needed to be consid-
ered while designing a suit-
able dermal formulation for 
poorly soluble compounds. In 
2013, Lai et al tested nano-
suspensions prepared by sim-
ple precipitation method as 
a tool to improve cutaneous 
targeting and photostabili-
ty of tretinoin, a poor water 
soluble and instable mole-
cule, commercially formulat-
ed in cream and gel forms for 
the treatment of acne vulgar-
is [64]. Drug skin permeation 
and deposition were studied 
in vitro by diffusion exper-
iments through new born pig 
skin while TRA photostability 
was investigated by irradiat-
ing samples with UV light. As 
an appropriate comparison, an 
O/W nanoemulsion was also pre-
pared and tested. Indeed, na-
noemulsions have shown to be 
particularly useful as vehi-
cle for dermal and transder-
mal delivery of hydrophobic 
compounds for pharmaceuti-
cal, cosmetic, and chemical 
industry applications. Dur-
ing 8 h percutaneous exper-
iments, the nanosuspension 
was able to localize the drug 
into the pig skin with a very 
low transdermal drug deliv-
ery (which is responsible of 
systemic side effects of this 
drug), whereas the nanoemul-
sion greatly improved drug 
permeation. Therefore, also 
this work demonstrated the 
high potentiality of nanosus-
pensions in dermal drug de-
livery. It is worth to notice 
that nanosuspensions are al-
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most exclusively composed of 
the drug nanoparticles with 
small amounts of biocompatible 
and safe surfactants, such as 
the soy lecithin used in this 
work and although only few 
toxicological data are avail-
able at the moment, no side 
effects are known or expect-
ed from nanocrystal topically 
applied. Indeed, as suggested 
by Muller et al., each sol-
id macro/micro-particle ap-
plied on the skin will con-
vert to nanocrystals during 
its dissolution process and, 
up to now, no intolerabili-
ty has been reported [12]. As 
already reported above, also 
in this research paper au-
thors justified the increased 
drug dermal delivery as a 
consequence increased of con-
centration gradient between 
the dermal formulation and 
the skin. More specifically, 
they claimed that finely di-
vided and uniformly suspended 
tretinoin nanocrystals pos-
sess an increased dissolution 
rate due to their large sur-
face area and increased satu-
ration solubility. Solid drug 
dissolves in the vehicle, dif-
fuses through the vehicle to 
the skin, establishes local 
phase equilibrium with the 
outer layer of skin and fi-
nally thanks to the larger 
concentration gradient pene-
trates the skin forming a de-
pot in the lipophilic SC from 
which it diffuses. Further-
more, the topical application 
of tretinoin nanocrystals has 
the advantage of increasing 
the drug photostability, in 
comparison with the control 
nanoemulsion.
In the last two years, the ap-
plication of nanocrystal tech-
nology have been extended to 
medium soluble compounds and 
a new mechanism by which na-
nocrystals can improve dermal 
delivery has been proposed, 
in addition to the simple in-
crease of concentration gra-
dient between formulation and 
skin [120]. This second mech-
anism involve the hair fol-
licles. Nanocrystals with an 
appropriated size (approxi-
mately 700nm) can accumulat-
ed into these shunts, which 
act as a depot from which the 
drug can diffuse into the sur-
rounding cells for prolonged 
release [126,127]. In a nov-
el interesting paper, Zhai et 
al produce nanocrystals with 
the aim of increasing the 
skin penetration of a medi-
um soluble active such as caf-
feine [128]. Moreover, they 
developed a specific produc-
tion process, namely a low 
energy milling in low dielec-
tric constant dispersion me-
dia and a selected stabiliz-
er, which allowed to overcome 
crystal growth and fiber for-
mation caused by supersatura-
tion and re-crystallization 
effects, typical with medium 
soluble compounds. The nov-
el concept introduced by Zhai 
et, consisted of formulating 
nanocrystals from medium sol-
uble actives, and applying a 
dermal formulation containing 
additionally nanocrystals, 
which should act as fast dis-
solving depot, increase satu-
ration solubility and accumu-
late in the hair follicles, to 
further enhance skin penetra-
tion. For this purpose, they 
produced caffeine nanocrys-
tals with varied size rang-
ing from 660 nm (optimal for 
hair follicle accumulation) 
to 250 nm (optimal for fast 
dissolution), by pear milling 
process in ethanol/propylene 
glycol 3:7 with 2% carbopol. 
As state by authors, select-
ed formulations are currently 
being tested in vivo in a hu-
man study.
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often appear following chron-
ic oral administration [3]. 
Therefore, a topical DCF for-
mulation with improved skin 
permeation may be useful in 
the treatment of not only lo-
cal skin inflammation but also 
inflammation and pain involv-
ing deeper structures such as 
bones, joints and muscles.
Since 1973, several pharma-
ceutical preparations have 
been developed for DCF appli-
cation to the skin, and a va-
riety of DCF salt products are 
currently available on the 
market. By contrast, because 
of its low water solubility, 
no DCF acid based commercial 
product exists. Indeed, even 
though this molecule possess-
es a good permeation rate due 
to its high lipophilicity, 
poor solubility causes a slow 
release rate from the formu-
lation which in turn limits 
the penetration and permea-
tion of an effective drug con-
centration into and through 
the skin. The final result is 
low dermal drug bioavailabil-
ity. In order to overcome the 
slow dissolution rate of such 
drugs, various approaches 
have been studied such as the 
1. Introduction
Diclofenac (DCF) (Figure 1) 
is one of the most commer-
cially successful non-steroi-
dal anti-inflammatory drugs 
(NSAIDs), which was launched 
by Ciba–Geigy as a sodi-
um salt oral formulation in 
1973. As all NSAIDs, DCF ex-
erts anti-inflammatory, anal-
gesic and anti-pyretic ac-
tions via inhibition of the 
cyclooxygenase I (COX 1) and 
cyclooxygenase II (COX II) 
enzymes [1]. However, re-
cent research indicates that 
the pharmacologic activity of 
DCF goes beyond COX inhibi-
tion and includes multimodal 
and, in some instances, nov-
el mechanisms of action, such 
as inhibition of the throm-
boxane-prostanoid receptors 
or inhibition of lipoxygenase 
enzymes and activation of the 
nitric oxide-cyclic guano-
sine monophosphate pathway 
[2]. DCF is widely prescribed 
for the treatment of a varie-
ty of localized pain and in-
flammatory conditions includ-
ing arthritis and soft tissue 
injuries. Although it is one 
of the best-tolerated NSAIDs, 
several systemic drawbacks 
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Figure 1 Diclofenac acid (DCF) structure
use of surfactants, co-sol-
vents, inclusion and compl-
exation compounds. These ap-
proaches have been related to 
different side effects includ-
ing skin irritation and can 
be only used for drugs having 
specific characteristics (suf-
ficient solubility in lipo-
philic excipients, appropri-
ate shape and molecular size 
for incorporation in cyclo-
dextrin etc.) [4].
An alternative to such meth-
ods is the nanonization of 
pure drug crystals with the 
preparation of the so-called 
nanocrystals (100-1000 nm), 
one of the most interesting 
drug delivery technologies of 
the last twenty years.
Nanocrystals are prepared as 
a suspension (nanosuspension) 
in an outer liquid phase, 
usually water but also water 
miscible liquids or non-aque-
ous media. Nanosuspensions 
are stabilized using ionic 
stabilizers (sodium dodecyl 
sulfate, lecithin, etc.) or 
non-ionic surfactants (Plu-
ronic® surfactants, polyeth-
ylene glycol, Tween 80, pol-
yvinylpyrrolidone, cellulose 
polymers, etc.).
Fundamentally, nanosuspen-
sions can be prepared by bot-
tom up or top down technol-
ogies or by a combination 
of both [5]. In the bottom 
up technology, the low wa-
ter soluble drugs are (molec-
ularly) dissolved in a sol-
vent and then precipitated in 
different ways as nanocrys-
tals in a surfactant solution 
[6]. The top down technology 
is based on particle disinte-
gration techniques including 
beads wet milling (Ghosh et 
al., 2012; Merisko-Liversidge 
et al., 2003) and high pres-
sure homogenization [10,11].
Nanosuspensions have been 
studied for different routes 
of administration; howev-
er, the oral one has been 
the most studied because of 
the improved clinical effica-
cy, the main advantages be-
ing enhanced bioavailability, 
reduced fed/fasted state and 
subject variability. There-
fore, the currently approved 
and marketed nanocrystal 
based products are mainly for 
oral administration [12].
Until now, the use of nano-
crystals for dermal appli-
cations has not been inten-
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sively studied and only a few 
articles regarding this top-
ic have been published [13–
16]. However, this technology 
could be very effective for im-
proving dermal bioavailabil-
ity of lipophilic substances 
with good skin permeability, 
such as DCF acid.
The aim of the present in-
vestigation was to study the 
ability of nanocrystal tech-
nology to improve the dermal 
bioavailability of the poorly 
water-soluble drug DCF acid. 
In order to investigate the 
role of the nanocrystal pol-
ymorphic structure in cuta-
neous bioavailability, two 
different DCF acid polymor-
phic forms (HD1 and HD2) were 
used to prepare nanosuspen-
sions using a wet media mill-
ing technique with poloxamer 
188 as a stabilizer. 
Characterization of DCF nano-
suspensions was carried out by 
different techniques: scanning 
electron microscopy (SEM), 
differential scanning calorim-
etry (DSC), X-ray powder dif-
fractometry and photon cor-
relation spectroscopy (PCS). 
The efficacy of the nanocrys-
tals in improving dermal drug 
bioavailability was evaluated 
by in vitro skin penetration 
and permeation studies using 
Franz diffusion vertical cells 
and newborn pig skin, in com-
parison with DCF coarse sus-
pension and a commercial top-
ical formulation containing 
diclofenac sodium.
2. Experimental 
2.1 Materials
Diclofenac sodium salt (DCF-
Na) was purchased from Galeno 
(Comeana, Italy). Lutrol® F68 
(Poloxamer 188) was a gift 
from BASF AG (Ludwigshafen, 
Germany). DCFNa commercial 
formulation, Diclofenac San-
doz® gel 1% is produced by 
Sandoz S.p.a. (Origgio, Va-
rese, Italy). All the other 
compounds were of analytical 
grade and used as received 
from Sigma–Aldrich (Milan, 
Italy).
2.2. Preparation of DCF acid 
crystal forms
HD2 DCF acid crystal form was 
obtained following the proce-
dure reported in a previous 
work [17]. Briefly, a saturat-
ed aqueous solution of di-
clofenac sodium salt was acid-
ified with diluited HCl until a 
white precipitate of DCF acid 
was observed. The precipitate 
was filtered, washed with bi-
distilled water to remove re-
sidual HCl and dried at 40°C 
overnight. Starting from HD2 
DCF satured solution in di-
methyl sulfoxide (DMSO), HD1 
DCF acid crystal form was ob-
tained by precipitation with 
bidistillated water. The pre-
cipitate was washed with the 
minimum amount of bidistilled 
water and after several cy-
cles of centrifugation was 
dried at 40 °C overnight.
2.3. Preparation of coarse 
suspensions
Coarse drug suspensions were 
prepared dispersing HD1 or 
HD2 DCF acid bulk powder in 
Poloxamer 188 bidistilled wa-
ter solution using an Ultra 
Turrax T25 basic (IKA, Werke) 
for 2 min at 6500 rpm. DCF 
acid coarse suspensions were 
prepared using both the same 
drug amount of the commer-
cial gel formulation (0.0031 
mol/100g, CS HD1 I and CS 
HD2 I) and the double amount 
(0.0062 mol/100g, CS HD1 II 
and CS HD2 II). Drug/sur-
factant ratio (w/w) was 2:1 
(Table 1).
2.4. Preparation of nanosus-
pensions
Nanosuspensions were pre-
pared using a wet media mill-
ing technique. Drug bulk 
powder (HD1 or HD2) was dis-
persed in aqueous Poloxam-
er 188 solution using an Ul-
tra Turrax T25 basic for 5 
min at 6500 rpm (Table 1)This 
coarse suspension was divid-
ed in 1.5 ml conical micro-
tubes containing about 0.4 g 
of 0.1-0.2 mm yttrium-stabi-
lized zirconia-silica beads 
(Silibeads® Typ ZY Sigmund 
Lindner, Germany). The micro-
tubes were oscillated at 3000 
rpm for different times using 
a beads-milling cell disrup-
tor equipment (Disruptor Ge-
nie®, Scientific Industries, 
USA). The obtained nanosus-
pensions of each microtubes 
were gathered and then sepa-
rated from the milling beads 
by sieving.
DCF acid nanosuspensions were 
prepared using both the same 
drug amount of the commer-
cial gel formulation (0.0031 
mol/100g, NS HD1 I and NS 
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HD2 I) and the double amount 
(0.0062 mol/100g, NS HD1 II 
and NS HD2 II). Drug/sur-
factant ratio (w/w) was 2:1 
(Table 1).
2.5. Solubility studies
DCF acid solubility was meas-
ured for both HD1 and HD2 bulk 
powders, coarse suspensions 
and nanosuspensions. Formu-
lations were kept under con-
stant stirring for 48 h in a 
thermostated bath at 37 °C. At 
preselected time intervals, 
samples were withdrawn and 
centrifuged. 0.2 ml of the 
clear supernatant was diluted 
with methanol and analyzed by 
HPLC for DCF content. Solu-
bility studies were performed 
in triplicate.
2.6. HPLC analysis
DCF content was quantified at 
280.4 nm using a chromatograph 
Alliance 2690 (Waters, Milan, 
Italy), equipped with a pho-
todiode array detector and a 
computer integrating appara-
tus (Empower 3). The column 
was a SunFire C18 (3.5 μm, 
4.6 mm × 100 mm, Waters), and 
the mobile phase was a mix-
ture of 30% water and 70% ace-
tonitrile (v/v), delivered at 
a flow rate of 0.7 ml/min.
A standard calibration curve 
was built up by using working 
standard solutions. Calibra-
tion graphs were plotted ac-
cording to the linear regres-
sion analysis, which gave a 
correlation coefficient value 
(R2) of 0.999.
2.7. Particle size analysis
Average diameter and polydis-
persity index (PI, as a meas-
ure of the size distribution 
width) of the samples were 
determined by photon corre-
lation spectroscopy (PCS) us-
ing a Zetasizer nano (Malvern 
Instrument, Worcestershire, 
United Kingdom). Samples were 
backscattered by a helium-ne-
on laser (633 nm) at an angle 
of 173° and a constant tem-
perature of 25°C. Zeta po-
tential was estimated using 
the Zetasizer nano by means 
of the M3-PALS (Phase Anal-
ysis Light Scattering) tech-
nique. Just before the analy-
sis, DCF nanosuspensions were 
diluted with distilled water. 
Nanocrystals average diameter 
and PI were monitored over 90 
days storage at room temper-
ature to check nano formula-
tion physical stability.
2.8. Differential scanning 
calorimetry
Differential scanning calorim-
etry (DSC) was performed with 
PerkinElmer DSC7 instrument, 
under a pure argon flux and 
with a heating rate of 10 °C/
min in the temperature range 
from 30 °C to 190 °C. Each 
sample was accurately weight-
ed (1–2 mg) in an aluminum 
pan, crimped and sealed. Tem-
perature calibration was ob-
tained using palmitic acid 
and indium before and after 
each measurement. At least 
three different measurements 
were made for each sample and 
average values of Tpeak (peak 
maximum) and Tonset (extrapo-
lated onset temperature) were 
reported.
2.9. X-ray powder diffractom-
etry
X-ray diffraction powder 
(XRDP) patterns were collect-
ed with a SeifertX3000 dif-
fractometer operating at 35 
mA and 40 kV using Cu Ka ra-
diation and equipped with a 
graphite monochromator on the 
diffracted beam. XRDP pat-
terns were recorded in step 
scan mode in the range 3° ≤2J 
≤45° with step size 0.05 2J 
degree, collecting at least 
1000 counts for each step. 
The divergence and receiv-
ing slits were chosen in or-
der to ensure a high resolu-
tion mode for the crystalline 
phases. Attention was paid 
in the sample preparation in 
order to minimize preferred 
orientation. Average crys-
talline size was estimated by 
Scherrer equation where the 
integral breadth was correct-
ed for instrumental broaden-
ing. The instrumental profile 
broadening was derived from 
the fitting of XRDP data ob-
tained from standard samples.
2.10. Scanning electron mi-
croscopy (SEM)
The morphology of pure HD1 and 
HD2 bulk powder and nanosus-
pensions was evaluated using 
scanning electron microscopy 
(SEM) (S-4100, HITACHI). The 
samples were fixed on a brass 
stub using carbon double-sid-
ed, coated with gold blazers 
SCD 004 sputter coater for 2 
minutes and observed under an 
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excitation voltage of 10 kV.
2.11. In vitro skin penetra-
tion and permeation studies
Experiments were performed 
on newborn pig skin using 
Franz vertical cells with 
an effective diffusion area 
of 0.785 cm2, under non-oc-
clusive conditions. One-day-
old Goland–Pietrain hybrid 
pigs (∼1.2 kg) were provid-
ed by a local slaughterhouse. 
The skin, stored at –80 °C, 
was pre-equilibrated in sa-
line (0.9% w/v of NaCl) at 
25 °C. Skin specimens (n = 6 
per formulation) were sand-
wiched between donor and re-
ceptor compartments. The re-
ceptor was filled with 5.5 
ml of saline, continuously 
stirred and thermostated at 
37 ± 1 °C to reach the phys-
iological skin temperature 
(i.e. 37 ± 1°C). HD1 and HD2 
nanosuspensions, coarse sus-
pensions and the commercial 
gel formulation (Diclofenac 
Sandoz® gel 1%) were placed 
onto the skin surface. Exper-
iments were carried out us-
ing DCF acid nanosuspensions 
and coarse suspensions with 
both the same drug amount 
of the commercial gel formu-
lation (3.1 μmoles) and the 
double amount (6.2 μmoles). 
At regular intervals, up to 
8 h, the receiving solution 
was entirely withdrawn, re-
placed with pre-thermostated 
(37 °C) fresh saline to ensure 
sink conditions and analysed 
by HPLC for drug content. Af-
ter 8 h, the skin surface was 
gently washed (3 times) with 
1 ml of distilled water, then 
dried with filter paper. The 
stratum corneum (SC) was re-
moved by stripping with ad-
hesive tape Tesa®AG (Ham-
burg, Germany). Each piece of 
the adhesive tape was firmly 
pressed on the skin surface 
and rapidly pulled off with 
one fluent stroke. Epider-
mis was separated from dermis 
with a surgical scalpel. Tape 
strips, epidermis and dermis 
were cut, placed each in a 
flask with methanol and son-
icated for 4 min in an ice 
bath to extract the drug. The 
tapes and tissue suspensions 
were filtered out and assayed 
for drug content by HPLC.
2.12 Statistical analysis of 
data
Data analysis was carried out 
with the software package 
R, version 2.10.1. Results 
are expressed as the mean ± 
standard deviation. Multiple 
comparisons of means (Tuk-
ey test) were used to sub-
stantiate statistical differ-
ences between groups, while 
Student’s t-test was used for 
comparison between two sam-
ples. Significance was tested 
at the 0.05 level of proba-
bility (p).
3. Results and Discussion
3.1. Preparation and charac-
terization of DCF acid nano-
suspensions
In this study, four different 
DCF acid nanosuspensions were 
prepared, characterized and 
tested as (trans)dermal drug 
delivery systems in compar-
ison with the corresponding 
coarse suspensions and a com-
mercial cream containing di-
clofenac sodium. 
As shown in Table 1, the na-
nosuspension formulations, 
which were prepared by the 
wet media milling process, 
contained both DCF acid crys-
tal forms, HD1 or HD2, at 
two different concentrations. 
These DCF acid concentra-
tions, 0.92% and 1.84% (w/w), 
were selected in order to ob-
tain coarse suspensions and 
nanosuspensions with the same 
(0.0031 mol/100g) or double 
(0.0062 mol/100g) the DCF mo-
larity of the DCFNa commer-
cial formulation used as con-
trol. Poloxamer 188 was chosen 
as the stabilizer since it 
is a generally recognized as 
safe (GRAS) excipient, bio-
compatible and, therefore, 
suitable for dermal appli-
cations. The drug/stabiliz-
er ratio was kept constant at 
2:1 w/w, which, according to 
our previous research [17], 
had shown high stability when 
nanosuspension formulations 
were prepared with this drug/
poloxamer 188 ratio.
Preliminary tests were carried 
out to determine the appro-
priate operative conditions 
for nanosuspension prepara-
tion. In particular, average 
diameter and PI modifications 
were studied as a function of 
the milling time. As shown in 
Figure 2, after 10 minutes of 
milling at 3000 rpm, the mean 
size of all formulations sig-
nificantly decreased, reach-
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Components (% w/w) Formulations 
 NS HD1 I 
(CS HD1 I)
NS HD1 II 
(CS HD1 II) 
NS HD2 I 
(CS HD 2 I) 
NS HD2 II 
(CS HD2 II) 
HD1  0.92 1.84 - - 
HD2  - - 0.92 1.84 
Poloxamer 188 0.46 0.92 0.46 0.92 
Water 98.62 97.24 98.62 97.24 
 
 
Z-AVE (nm) PI ZP (mV) 
NS HD1 I 315± 5 0.25 ± 0.10 -35 
NS HD1 II 284 ± 6 0.20 ± 0.04 -35 
NS HD2 I 279 ± 8 0.17 ± 0.01 -35 
NS HD2 II 304 ± 4 0.23 ± 0.04 -39 
Table 2 Average diameter (Z-AVE), polydispersity index (PI) and Zeta potential 
(ZP) of HD1 and HD2 freshly prepared nanosuspensions. Each value is the mean ± 
standard deviation of at least six experimental determinations.
Table 1 Composition of HD1 and HD2 coarse suspension (CS HD2 II, CS HD2 I, CS 
HD1 II, CS HD1 I) and nanosuspension formulations (NS HD2 II, NS HD2 I, NS HD1 
II, NS HD1 I
ing a mean diameter below 1 
μm. By increasing the mill-
ing duration, all formula-
tions showed both size and PI 
values reduction. In particu-
lar, formulations containing 
0.92% (w/w) DCF (either HD1 
or HD2) required 60 minutes 
to reach the minimal value in 
mean diameter and an accept-
able homogeneity.
When the concentration of the 
drug was doubled (1.84% w/w), 
the milling time required to 
reach the smallest size was 
70 minutes. Increasing the 
milling time further did not 
result in additional reduc-
tion of the nanocrystal size.
In light of these results, 
nanosuspensions were prepared 
using the following operating 
conditions: 60 or 70 minutes 
of milling time at 3000 rpm 
for 0.92% (0.0031 mol/100g) or 
1.84% (0.0062 mol/100g) drug 
concentration, respectively. 
Table 2 reports the PCS meas-
urements of the freshly pre-
pared HD1 and HD2 nanosus-
pensions. No significant 
differences were found between 
average particle diameters in 
formulations prepared with 
the two polymorphic forms, 
thus indicating that this fac-
tor did not influence the par-
ticle dimensions of the stud-
ied nanosuspensions. Freshly 
prepared formulations exhib-
ited a mean diameter ranging 
between 279 e 315 nm and a 
PI lower than 0.25. Formula-
tion NS HD2 I (HD2, 0.0031 
mol/100g) showed the lowest 
mean size and PI values (279 
nm and 0.17 PI). The zeta po-
tential values were highly 
negative (-35 mV).
The stability of the nanosus-
pension was evaluated by mon-
itoring the size distribution 
during 90 days of storage at 
room temperature (∼25 C). As 
shown in Figure 3, particle 
size and PI values of all the 
studied nanosuspensions in-
creased after 90 days of stor-
age, except NS HD2 I. An in-
crease in size of ∼40%, ∼50% 
and ∼60% was observed for for-
mulation NS HD1 I, NS HD1 II 
and NS HD2 II, respectively. 
By contrast, formulation NS 
HD2 I, with the smallest ini-
tial values, retained similar 
mean diameter and PI values 
during the 90 days of stor-
age (∼315 nm and 0.19 PI). The 
morphological changes of HD1 
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Figure 2 Average diameter (Z-average) and polydispersity index (PI) of nanosus-
pension formulations as function of milling time.
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Figure 3 Average diameter (Z-average) and polydispersity index (PI) of nanosus-
pension formulations monitored during 90 days of storage at room temperature. 
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Figure 4.a. SEM images of HD1 raw material. 
and HD2 crystals after the 
milling process were evalu-
ated by SEM imaging. As seen 
in Figure 4, the milling pro-
cess modified both the shape 
and size of HD1 and HD2 crys-
tals. In the milling process, 
high shear forces are gener-
ated during collision of the 
drug crystals with the yttri-
um-stabilized zirconia-sili-
ca beads and with the wall 
of the tubes, which provide 
the energy to break the drug 
crystals down to the nanom-
eter range. Before milling, 
raw drug material (Figure 
4a) had large crystals with a 
regular elongated shape. Af-
ter milling, in the presence 
of stabilizers, the large 
HD1/HD2 crystals were reduced 
into nanocrystals, with an-
gular surfaces much smooth-
er and rounded (Figure 4b-c). 
The size of the nanocrys-
tals shown in the SEM images 
are well in accordance with 
the results obtained by PCS, 
which demonstrated that the 
particle size of the nano-
suspensions were approximate-
ly 100 times smaller (0.3-0.5 
μm) than that of HD1 or HD2 
coarse powders (10-50 μm).
X-ray diffraction powder 
(XRDP) spectra of yttri-
um-stabilized zirconia-sili-
ca beads, poloxamer 188, bulk 
HD1 and bulk HD2 are reported 
in Figure 5. The diffraction 
pattern of poloxamer 188 is 
typical of crystalline poly-
meric materials and is char-
acterized by a peak around 19° 
2θ and a second broader peak 
centered at 23° 2θ (Figure 5). 
XRDP spectra of yttrium-sta-
bilized zirconia-silica beads 
exhibit Bragg peaks due to 
the crystalline yttrium and 
zirconium oxide mixtures with 
the strongest lines centered 
around 30.25° and 26.72° 2θ 
degree. The X-ray powder dif-
fraction patterns of bulk HD1 
and HD2, are those expected on 
the base of their structures: 
monoclinic P21/c and mono-
clinic C2/c crystal struc-
tures, respectively [18]. No 
peaks due to HD1 are present 
in the HD2 spectrum and vice 
versa. Peaks with Miller in-
dex (111/012), (111) (102), 
and (200) are used as finger-
prints to characterize this 
phase. Moreover, no peaks due 
to HD3 polymorphic form are 
detectable in both HD1 and 
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Figure 4.c. SEM images of HD2 nanosuspension.Figure 4.b. SEM images of HD1 nanosuspension.
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Figure 5 XRD spectra of Yttrium-stabilized zirconia-silica beads (beads), 
poloxamer, bulk HD2 and HD1 and nanosuspensions (NS HD2 II, NS HD2 I, NS HD1 
II, NS HD1 I).
HD2 spectra, thus, indicating 
that the media milling pro-
cess does not modify the DCF 
polymorphic form.
In the XRDP spectra of HD1 
and HD2 nanosuspensions, typ-
ical peaks due to poloxam-
er 188 are visible (peaks 
around 19° and 23° 2θ) while 
no peaks due to yttrium-sta-
bilized zirconia-silica are 
present. Therefore, this is 
a clear sign that no trace 
of yttrium-stabilized zirco-
nia-silica beads contaminat-
ed the nanosuspension dur-
ing the preparation process. 
Moreover, in all these spec-
tra, relative peak intensi-
ties show the same trend of 
bulk samples (Figure 5b) even 
if the peaks are broader as a 
result of the lower particle 
size. Indeed, the average di-
ameter values, calculated ac-
cording to the Scherrer equa-
tion [19], are in the range 
of 65–90 nm. Nevertheless, we 
cannot exclude a partial con-
tribution of structural dis-
order as the cause of the peak 
broadening. In more detail, 
XRDP spectra of the HD1 na-
nosuspensions show that peaks 
due to HD1 phase are slightly 
wide, hence, indicating crys-
talline size around 90 nm. On 
the other hand, the spectra of 
the HD2 nanosuspensions show 
that the HD2 phase peaks are 
wider than those of the HD1 
nanosuspensions, thus, indi-
cating a narrower crystalline 
size around 65 nm.
In conclusion, the XRDP analy-
sis confirmed that the different 
HD1 and HD2 bulk powder retain 
their polymorphic form in the 
prepared nanosuspensions.
Differential scanning calo-
rimetry (DSC) thermograms of 
the different components and 
formulations are reported in 
Figure 6. Bulk HD2 and HD1 
thermograms are characterized 
by a sharp endothermic peak 
followed by sample decomposi-
tion (Figure 6) [20]. In the 
thermograms of all nanosus-
pensions, the poloxamer endo-
thermic melting peak, around 
50°C, is always present. Tpeak 
and Tonset values of the bulk 
polymorphs and nanosuspen-
sion formulations are report-
ed in Table 3. Bulk HD2 sam-
ple melted at a temperature 
slightly lower (Tpeak 177.9 
°C) than that of the bulk HD1 
(Tpeak 179.0 °C). Thermograms 
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Figure 6 DSC thermograms of poloxamer, bulk HD2 and HD1 and nanosuspensions (NS 
HD2 II, NS HD2 I, NS HD1 II, NS HD1 I).
of the four nanosupensions 
are very similar and they are 
all characterized by a broad 
peak with Tpeak centered 
around 148-158°C. This behav-
ior, lower Tpeak and broad-
er peak compared to that of 
bulk powders, is in agreement 
with the Van’t Hoff equation 
[21] and is expected for mix-
tures like nanosuspensions. 
Slight differences in Tpeak 
(and Tonset) of the nanosus-
pension formulations can be 
due to the slight differences 
in the average particle size 
and PI, in agreement with the 
XRDP results.
3.2. In vitro skin penetra-
tion and permeation studies
To evaluate the effect of the 
reduced crystal size on der-
mal and transdermal deliv-
ery of DCF, in vitro penetra-
tion and permeation studies 
through newborn pig skin were 
carried out in non occlu-
sive conditions using Franz 
diffusion cells. Coarse sus-
pensions of both DCF crys-
tal forms (HD1 and HD2) and 
a commercial gel formulation 
were used as control. Figure 
7 shows the % of DCF moles de-
livered to and accumulated in 
the skin strata for nanosus-
pensions, coarse suspensions 
and commercial formulation 
prepared using the same DCF 
molar concentration (0.0031 
mol/100g), after an 8 h ex-
periment. As shown in Table 4, 
nanosuspensions enhanced DCF 
skin delivery compared to the 
coarse suspension and commer-
cial gel formulation, which 
showed the lowest drug deliv-
ery into and through the new-
born pig skin. In particular, 
nanosuspensions enhanced DCF 
skin accumulation by a factor 
of 12 over DCFNa commercial 
gel formulation (Table 4).
Indeed, as reported in Figure 
7, after application of the gel 
formulation, drug deposition 
into the skin was only 1.38% 
in the stratum corneum, 1.15% 
in the epidermis and 0.31% 
in the dermis. Also, the ap-
plication of nanosuspensions 
and coarse suspensions always 
gave the higher accumulation 
of DCF in the stratum cor-
neum. In particular, HD1 and 
HD2 nanosuspensions produced 
a drug accumulation in the SC 
approximately 16 times higher 
than the commercial gel and 7 
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   drug 
( mol/cm
2
±SD) ( mol/cm
2
±SD) ( mol/cm /h
2
±SD) 
Permeated
   drug
 Total drug 
delivered 
(%) 
LAC Lag time  
(h) 
J
Gel DCFNa 0.11±0.038 0.01±0.002 2.9 8.6 2.3 
CS HD1 I 0.16±0.074 - 3.7 - - - 
CS HD1 II 0.24±0.043 - 2.8 - - - 
CS HD2 I 0.72±0.167 - 16.8 - - - 
CS HD2 II 0.72±0.224 - 8.37 - - - 
NS HD1 I 1.05±0.134 0.04±0.014 33.6 27.3 2.0 0.005±0.0017
0.002±0.0003
0.003±0.0004
0.005±0.0012
0.003±0.0009
NS HD1 II 1.16±0.060 0.03±0.003 16.0 42.9 2.0 
NS HD2 I 1.16±0.111 0.04±0.010 32.9 30.4 2.2 
NS HD2 II 1.15±0.092 0.03±0.008 15.9 42.4 2.5 
Figure 7 Cumulative amount of DCF retained into and permeated through pig skin 
layers after 8 h application of HD1 and HD2 nanosuspensions (NS, 0.0031 mol/100g) 
in comparison with HD1 and HD2 coarse suspensions (CS, 0.0031 mol/100g) and Di-
clofenac Sandoz® gel 1% (0.0031 mol/100g). SC, stratum corneum; Ep, epidermis; 
D, dermis; and RC, receptor compartment.
Table 4 Amount of accumulated and permeated drug (μmol/cm2), total drug deliv-
ered (%), Local Accumulation Efficiency (LAC) values: drug accumulated into the 
skin/drug delivered through the skin ratio, steady-state flux (J µmol/cm2/h), 
lag time (h) after 8 h in vitro diffusion experiments of DCF nanosuspensions in 
comparison with DCF coarse suspensions and Diclofenac Sandoz® gel 1%. Values 
are the means ± standard deviation (n = 6).
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and 2 times higher than the 
corresponding coarse suspen-
sions. In addition, nanosus-
pensions were able to improve 
DCF deposition, with respect 
to coarse suspensions, in the 
epidermis and dermis, where 
they reached 7.8% (NS HD1 I) 
and 6.1% (NS HD2 I) in the 
epidermis and 2.5% (NS HD1 I 
HD1) and 3.3% (NS HD2 I) in 
the dermis. 
These outcomes indicate that 
DCF crystal size plays an im-
portant role in the ability 
of the drug to penetrate the 
stratum corneum barrier, due 
to the increased saturation 
solubility and dissolution 
rate of the nanocrystals, 
according to the Kelvin and 
Noyes–Whitney equations [22]. 
This leads to an increased 
concentration gradient be-
tween formulation and skin, 
thus enhancing drug penetra-
tion in comparison with the 
coarse suspension. DCF acid 
solubility values of HD1 and 
HD2 raw material, coarse and 
nanosuspension are report-
ed in Table 5. HD1 and HD2 
raw material showed a similar 
solubility value of approxi-
mately 20 μg/ml. The presence 
of the surfactant increased 
the water solubility of both 
HD1 and HD2 in the coarse sus-
pension (∼35 µg/ml). The size 
reduction from DCF coarse 
crystals to nanocrystals fur-
ther increased the DCF water 
solubility that increased to 
approximately 90 μg/ml.
In this study, the results of 
the transdermal experiments 
emphasize the influence of 
drug solubility on the abili-
ty of a poorly soluble drug to 
cross the skin and accumulate 
in the deeper skin layers.
In particular, we found that 
a reduction of approximate-
ly 100 times in size and an 
increase of approximately 3 
times in solubility were ob-
tained by producing nanocrys-
tals, which led to a total 
skin accumulation of DCF 4 
times higher than the coarse 
suspensions.
When coarse DCF is transformed 
into nanocrystals, drug sat-
uration solubility increases, 
namely the DCF acid molecules 
in solution in equilibri-
um with the solid phase in-
creases. These molecules are 
more lipophilic than the hy-
drophilic derivative (DCF-
ment, LAC values can easily 
be obtained as the ratio of 
DCF accumulated in the skin 
versus DCF delivered through 
the skin. LAC values obtained 
for the different applied for-
mulations are listed in Ta-
ble 4. The LAC value of both 
nanosuspensions was higher by 
a factor of 3.2–3.5 compared 
to the commercial gel formu-
lation, suggesting that the 
main effect of nanocrystals 
was to increase the drug ac-
cumulation in the skin.
In order to understand the 
relationship between the 
amount of drug applied on the 
skin surface and the amount 
of drug actually accumulated 
or permeated, HD1 and HD2 na-
nosuspensions and coarse sus-
pensions were also prepared 
using a double amount of DCF 
(0.0062 mol/100g) than that 
of commercial gel. In Figure 
8, the cumulative amount of 
DCF recovered from the dif-
ferent skin strata is report-
ed as the mean amount of drug 
per unit of surface area (μg/
cm2) after application of all 
the prepared formulations. As 
shown, when the same volume 
of suspension (coarse or na-
Na) and, therefore, afford in-
creased penetration into the 
skin. DCF molecules dissolve 
quickly from the nanocrys-
tals, which act as a depot 
in the water phase, and rap-
idly replace the DCF mole-
cules penetrated from the wa-
ter phase into the skin.
Furthermore, Table 4 and Fig-
ure 7 show that the two DCF 
crystal forms, HD1 and HD2, 
display different behavior 
when applied as large crys-
tals (coarse suspension). In 
fact, HD2 coarse suspensions 
(CS HD2 I) resulted in a high-
er accumulation into the skin 
strata compared with the HD1 
coarse suspension (CS HD1 I). 
By contrast, the release pro-
files and the skin deposition 
of the two nanosuspensions 
(NS HD1 I and NS HD2 I) were 
very similar, thus, demon-
strating that the two crystal 
polymorphs, HD1 and HD2, be-
have in the same manner when 
applied as nanocrystals.
A useful dimensionless pa-
rameter that allows for the 
evaluation and comparison of 
different topical carriers is 
local drug accumulation effi-
ciency (LAC). In our experi-
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Figure 8 Cumulative amount of DCF retained into and permeated through pig skin 
layers after 8 h application of nanosuspensions (NS) or coarse suspensions (CS) 
of HD1 and HD2 at two different concentrations: 0.0031 mol/100g (I) and 0.0062 
mol/100g (II) SC, stratum corneum; Ep, epidermis; D, dermis; and RC, receptor 
compartment.
nosuspension) but with a dou-
ble amount of the drug was 
applied, neither the accumu-
lation nor the permeation of 
the drug was increased. Dou-
bling the nanocrystal sol-
id phase does not affect drug 
skin penetration and perme-
ation because the DCF sat-
uration solubility remain 
constant.
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methods (ionophoresis, elec-
troporation and low-frequency 
ultra-sound) [5].
Transcutol® P (diethylene 
glycol monoethyl ether, TRC) 
is a powerful solubilizing 
agent used in several dos-
age forms and it seems to be 
very attractive as a pene-
tration enhancer due to its 
non-toxicity, biocompatibil-
ity with the skin, miscibil-
ity with polar and non-polar 
solvents and optimal solubi-
lizing properties for a num-
ber of drugs [6]. It has been 
suggested that Transcutol® 
can lead to formation of cu-
taneous depot of drugs due 
to its ability to cause in-
tercellular lipids swelling 
without altering stratum cor-
neum multiple bilayer struc-
ture [4,7,8]. However, Trans-
cutol has also been reported 
to increase the skin accumu-
lation of topically applied 
compounds without a concomi-
tant increase in transdermal 
permeation [9].
Moreover, one approach to in-
crease skin permeability of 
poorly water soluble drugs is 
the production of nanocrys-
tals (pure drug only stabi-
1. Introduction
There is great interest in 
the skin as route for both lo-
cal and systemic of drug ad-
ministration. Indeed, topi-
cal drug delivery has several 
advantages over other routes 
of administration such as re-
duction of drug systemic tox-
icity, improved bioavaila-
bility for drugs that suffer 
the gastrointestinal environ-
ment and/or hepatic first ef-
fects and also enhancement of 
drug local activity and pa-
tient compliance. However, 
the skin, in particular the 
stratum corneum (SC), forms 
a formidable barrier to drug 
penetration thereby limiting 
topical and transdermal bi-
oavailability. In order to 
overcome the impermeability 
of intact human skin and to 
enhance drug transport across 
the skin, several strategies 
have been developed. These 
strategies include passive 
and active penetration en-
hancement and technologies 
to bypass the stratum cor-
neum. They include chemical 
methods based on the use of 
different penetration enhanc-
ers [1–4] as well as physical 
4. The effect of Transcutol® on skin penetration 
ability of diclofenac acid nanosuspensions
The effect of Transcutol® on skin penetration ability of diclofenac 
acid nanosuspensions
159158 PhD Program XXVII - Nanosized systems for efficient delivery of antitu-
moral and anti-inflammatory drugs.
lized with a small amount of 
stabilizer). Conversion of 
the microsized drug particles 
into nanocrystals not only 
increases the dissolution ve-
locity [10,11], but also in-
creases the saturation sol-
ubility, which significantly 
improves the bioavailabili-
ty of the drug. An increase 
in the saturation solubility 
increases the concentration 
gradient between the dermally 
applied formulation and the 
skin [12,13].
The objective of this inves-
tigation was to develop Di-
clofenac acid (DCF) nano-
suspensions obtained by the 
addition of a permeation en-
hancer, Transcutol, in the 
aqueous stabilizer solution 
and to study the effect of 
Transcutol on the transder-
mal permeation and skin accu-
mulation of DCF nanocrystals. 
Diclofenac, 2-[(2,6-dichlo-
rophenyl)amino] phenylacetic 
acid, is a potent nonsteroidal 
anti-inflammatory drug (NSAID) 
with a very low aqueous sol-
ubility and gastrolesive ac-
tions. It is used in inflam-
matory and painful conditions 
of rheumatic and nonrheumatic 
origin [14]. Three polymor-
phic forms of diclofenac acid 
are reported: two are mono-
clinic and are referred as HD1 
(space group P21/c) and HD2 
(space group C2/c). In both 
forms molecules are linked to 
each other through the car-
boxyl groups giving rise to 
centrosymmetric dimers [15]. 
Third polymorph is an ortho-
rombic form (HD3, space group 
Pcan) where no intermolec-
ular hydrogen bond is pres-
ent [16]. In this study the 
polymorphic form HD2 has been 
used.
Characterization of 
DCF-TRC-nanosuspensions, pre-
pared using the wet media 
milling technique, was car-
ried out by different tech-
niques: scanning electron mi-
croscopy (SEM), differential 
scanning calorimetry (DSC), 
X-ray powder diffractometry 
(XRPD), Fourier transform in-
frared spectroscopy and pho-
ton correlation spectroscopy 
(PCS). The influence of Trans-
cutol concentration on skin 
penetration ability of DCF 
nanosuspensions was evaluated 
by in vitro skin penetration 
and permeation studies using 
Franz diffusion vertical cells 
and newborn pig skin, in com-
parison with DCF nanosuspen-
sion without TRC, DCF coarse 
suspension and a commercial 
topical formulation contain-
ing diclofenac sodium.
2. Experimental
2.1 Materials
Diclofenac sodium salt (DCF-
Na) was purchased from Gale-
no (Comeana, Italy). Dieth-
ylene glycol monoethyl ether 
(Transcutol® P, Trc) was 
kindly provided by Gattefosse 
(Saint Priest, France). DCF-
Na commercial formulation, 
Diclofenac Sandoz® gel 1% 
is produced by Sandoz S.p.a. 
(Origgio, Varese, Italy). 
Kolliphor® P188 (Poloxamer 
188) and all other reagents 
were purchased from Sigma–
Aldrich (Milan, Italy).
2.2. Preparation of DCF acid
Diclofenac acid crystal form 
(DCF) was obtained following 
the procedure reported in a 
previous work [14]. Briefly, 
a saturated aqueous solution 
of diclofenac sodium salt was 
acidified with diluted HCl un-
til a white precipitate of 
DCF acid was observed. The 
precipitate was filtered out, 
washed with bidistilled water 
to remove residual HCl and 
dried at 40°C overnight.
2.3. Preparation of DCF coarse 
suspension
The DCF coarse suspensions 
were prepared by dispersing 
DCF bulk powder in an aqueous 
system consisted of Poloxamer 
188 (0.46% w/w) and Transcutol 
in concentrations of 0, 0.5, 
1 or 5% (w/w) using an Ultra 
Turrax T25 basic (IKA, Werke, 
Germany) for 5 min at 6500 
rpm. For the preparation, the 
same drug amount of the com-
mercial gel formulation was 
used (3.1 mmol/100g).
2.4. Preparation and charac-
terization of DCF nanosuspen-
sions
Diclofenac nanosuspensions 
were prepared using a wet me-
dia milling technique. Drug 
bulk powder was dispersed in 
an aqueous system consisted of 
Poloxamer 188 (0.46% w/w) and 
Transcutol in concentrations 
of 0, 0.5, 1 or 5% (w/w) using 
an Ultra Turrax T25 basic for 
5 min at 6500 rpm (Table 1). 
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This coarse suspension was 
divided in 1.5 ml conical mi-
crotubes containing about 0.4 
g of 0.1-0.2 mm yttrium-sta-
bilized zirconia-silica beads 
(Silibeads® Typ ZY Sigmund 
Lindner, Germany). The micro-
tubes were oscillated at 3000 
rpm for 60 minutes using a 
beads-milling cell disruptor 
equipment (Disruptor Genie®, 
Scientific Industries, USA). 
The obtained nanosuspensions 
of each microtubes were gath-
ered and then separated from 
the milling beads by siev-
ing. DCF acid nanosuspensions 
were prepared using both the 
same drug amount of the com-
mercial gel formulation (3.1 
mmol/100g). 
The average diameter and 
polydispersity index (PI; a 
measure of the size distri-
bution width) of the nanosus-
pensions were determined by 
photon correlation spectros-
copy (PCS) using a Zetasiz-
er nano (Malvern Instruments, 
Worcestershire, United King-
dom). Samples were backscat-
tered by a helium–neon la-
ser (633 nm) at an angle of 
173° and a constant temper-
ature of 25 °C. Zeta poten-
tial was estimated using the 
Zetasizer nano by means of 
the M3-PALS (Phase Analysis 
Light Scattering) technique. 
Just before the analysis, the 
DCF nanosuspensions were di-
luted with bidistilled wa-
ter. DCF-Trc-nanosuspensions 
were evaluated using scanning 
electron microscopy (SEM) (S-
4100, HITACHI). Samples were 
fixed on a brass stub using 
carbon double-sided, coat-
ed with gold blazers SCD 004 
sputter coater for 2 minutes 
and observed under an excita-
tion voltage of 5 kV.
2.5. Solubility studies
The water solubility of DCF 
acid was measured for the DCF 
bulk powder, coarse suspen-
sions and nanosuspensions. 
Formulations (n=3) were kept 
under constant stirring for 
48 h in a thermostated bath 
at 37 °C. At preselected time 
intervals, samples were with-
drawn and centrifuged. 0.2 ml 
of the clear supernatant was 
filtrated, diluted with meth-
anol and analyzed by HPLC. 
DCF content was quantified at 
280.4 nm using a chromato-
graph Alliance 2690 (Waters, 
Milan, Italy), equipped with 
a photodiode array detector 
and a computer integrating 
apparatus (Empower 3). The 
column was a SunFire C18 (3.5 
μm, 4.6 mm × 100 mm, Waters), 
and the mobile phase was a 
mixture of 30% water and 70% 
acetonitrile (v/v), delivered 
at a flow rate of 0.7 ml/min. 
A standard calibration curve 
was built up by using working 
standard solutions. Calibra-
tion graphs were plotted ac-
cording to the linear regres-
sion analysis, which gave a 
correlation coefficient value 
(R2) of 0.999.
2.6. Differential scanning 
calorimetry
Differential scanning calorim-
etry (DSC) was performed with 
a Perkin Elmer DSC7, under 
a pure argon flux and with a 
heating rate of 10 °C/min in 
the temperature range from 30 
to 190 °C. Each sample was ac-
curately weighed (1–2 mg) in 
an aluminum pan, crimped and 
sealed. Temperature calibra-
tion was obtained using pal-
mitic acid and indium before 
and after each measurement. 
At least three different meas-
urements were made for each 
sample and average values of 
Tpeak (peak maximum) and Ton-
set (extrapolated onset tem-
perature) were reported.
2.7. X-ray powder diffractom-
etry
X-ray powder diffraction (XRPD) 
patterns were collected with 
a Seifert X3000 diffractome-
ter operating at 35 mA and 
40 kV using Cu Kα radiation 
and equipped with a graphite 
monochromator on the diffract-
ed beam. XRPD patterns were 
recorded in step scan mode in 
the range 3°≤2θ≤45°, with step 
size 0.05 2θ degree, collect-
ing at least 1000 counts for 
each step. The divergence and 
receiving slits were chosen in 
order to ensure a high resolu-
tion mode for the crystalline 
phases. Attention was paid 
in the sample preparation in 
order to minimize preferred 
orientation. Average crystal-
line size was estimated by the 
Scherrer equation, where the 
integral breadth was correct-
ed for instrumental broaden-
ing. The instrumental profile 
broadening was derived from 
the fitting of XRPD data ob-
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tained from standard samples.
2.8. Fourier transform infra-
red spectroscopy (FTIR)
The FTIR spectra of the sam-
ples, dispersed in KBr pel-
let, were obtained using a 
Bruker Vector 22 spectropho-
tometer within the 4000– 400 
cm−1 range. Transcutol spec-
trum was obtained dipping few 
drop of liquid sample onto 
KBr disk.
2.9. In vitro skin penetra-
tion and permeation studies
Experiments were performed on 
newborn pig skin using Franz 
vertical cells with an effec-
tive diffusion area of 0.785 
cm2, under non-occlusive con-
ditions. One-day-old Go-
land–Pietrain hybrid pigs 
(∼1.2 kg) were provided by 
a local slaughterhouse. The 
skin, stored at –80 °C, was 
pre-equilibrated in saline 
(0.9% w/v of NaCl) at 25 °C. 
Skin specimens (n = 12 per 
formulation) were sandwiched 
between donor and recep-
tor compartments. The recep-
tor was filled with 5.5 ml of 
saline, continuously stirred 
and thermostated at 37 ± 1 
°C to reach the physiological 
skin temperature (i.e. 37 ± 
1°C). 100 μl of each formula-
tion were placed onto the skin 
surface. Experiments were 
carried out using DCF acid na-
nosuspensions and coarse sus-
pensions with both the same 
drug amount of the commercial 
gel formulation (3.1 μmoles). 
At regular intervals, up to 
8 h, the receiving solution 
was entirely withdrawn, re-
placed with pre-thermostated 
(37 °C) fresh saline to ensure 
sink conditions and analysed 
by HPLC for drug content. Af-
ter 8 h, the skin surface was 
gently washed (3 times) with 
1 ml of distilled water and 
then dried with filter paper. 
The stratum corneum (SC) was 
removed by stripping with ad-
hesive tape Tesa®AG (Ham-
burg, Germany). Each piece of 
the adhesive tape was firmly 
pressed on the skin surface 
and rapidly pulled off with 
one fluent stroke. Epider-
mis was separated from dermis 
with a surgical scalpel. Tape 
strips, epidermis and dermis 
were cut, placed each in a 
flask with methanol and son-
icated for 4 min in an ice 
bath to extract the drug. The 
tapes and tissue suspensions 
were filtered out and assayed 
for drug content by HPLC.
3. Results and Discussion
3.1. Preparation and charac-
terization of DCF-TRC-nano-
suspensions
During this study, prepa-
ration, physico-chemical 
properties and (trans)der-
mal drug delivery ability of 
DCF-TRC-nanosuspensions were 
evaluated. In particular, the 
effect of different concentra-
tions of Transcutol in the 
nanosuspension formulations 
(0.5, 1 and 5% for NS-TRC 
0.5%, NS-TRC 1% and NS-TRC 
5%, respectively) was studied 
and, as a comparison, a nano-
suspensions without Transcu-
tol (NS-TRC 0%) was prepared 
(Table 1). All nanosuspen-
sions were prepared by the 
wet media milling technique, 
using as operating condi-
tions 60 minutes of milling 
time at 3000 rpm and Polox-
amer 188 (0.48% w/w) as sta-
biliser. The properties of 
freshly prepared nanosuspen-
sions are shown in Table 2. As 
can be seen, nanosuspensions 
with Transcutol exhibited a 
mean diameter of ∼350 nm and a 
polydispersity index ranging 
between 0.21 and 0.26, values 
greater than those of the na-
nosuspension without TRC (NS-
TRC 0%). The zeta potential 
values were highly negative, 
∼-35 mV, and increasing TRC 
concentration increases the 
nanosuspension pH value which 
remains always acid (pH<6). 
The morphological features of 
DCF nanocrystals were evalu-
ated by SEM imaging. As seen 
in Figure 1, even with Trans-
cutol, DCF nanocrystals were 
nanosized with smooth and 
rounded surfaces. However, 
particle size distribution is 
broader than nanosuspensions 
without TRC (see page 143), 
in accordance with the re-
sults obtained by PCS. 
In the XRDP pattern of DCF 
nanosuspension without Trans-
cutol and TRC-nanosuspensions 
(Figure 2), peaks due to po-
laxamer are visible (peaks 
around 19 and 23 2J degree) 
while no peaks due to bead 
are present. The XRDP re-
sults of nanosuspension in-
dicate that no polymorphic 
transition took place during 
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Components (% w/w) Formulations 
 NS-TRC 0% NS-TRC 0.5% NS-TRC 1% NS-TRC 5%
DCF  0.92 0.92 0.92 0.92 
Poloxamer 188 0.46 0.46 0.46 0.46 
Transcutol - 0.5 1 5 
Water 98.6 98.1 97.6 93.6 
NS-TRC 0%
NS-TRC 0.5%
NS-TRC 1%
NS-TRC 5%
Z-AVE (nm) PI ZP (mV) pH 
279.2±8.12
346.1±14.17
355.7±3.31
349.5±14.32
 0.17 ± 0.01
0.21 ± 0.05
0.26 ± 0.02
0.22 ± 0.02
-35.0 ± 1.32
-36.9 ± 2.86
-37.8 ± 0.87
-37.2 ± 1.10
4.4 
5.28 
5.13 
5.95 
Table 1 Composition of DCF nanosuspensions
Table 2 Average diameter (Z-AVE), polydispersity index (PI), Zeta potential 
(ZP) and pH of DCF freshly prepared nanosuspensions. Each value is the mean ± 
standard deviation of at least six experimental determinations.
Figure 1.a. SEM images of Diclofenac acid (DCF) nanosuspensions with 0.5% TRC 
concentrations: NS-TRC 0.5%.
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Figure 1.c. SEM images of Diclofenac acid (DCF) nanosuspensions with 5% TRC 
concentrations: NS-TRC 5%.
Figure 1.b. SEM images of Diclofenac acid (DCF) nanosuspensions with 1% TRC 
concentrations: NS-TRC 1%.
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milling. In all these spec-
tra the relative peak inten-
sities due to DCF and Polox-
amer phases have the trend of 
those of bulk samples. XRDP 
patterns of bulk DCF (Figure 
2c), is in agreement with the 
HD2 monoclinic C2/c crystal 
structure and all peaks are 
indexed using these structur-
al data [15]. Amorphous con-
tribution of liquid Transcu-
tol was not observed. In the 
nanosuspensions samples peaks 
due to HD2 phase were rath-
er broad as a result of lower 
particle size, whose average 
values calculated according 
to Scherrer equation result 
in the nanometer range. The 
HD2 phase peaks width in the 
XRDP spectra of nanosuspen-
sions prepared whitout Trans-
cutol (Figure 2d) indicates 
a narrow crystalline size 
around 60 nm. The width anal-
ysis of the same peaks in the 
TRC-nanosuspensions leads to 
an average crystalline size 
around 84 nm for TRC 0.5% and 
TRC 1% while those of TRC 5% 
are smaller (77 nm). 
In conclusion, the XRDP anal-
ysis indicates a crystalline 
average size in NS-TRC 0% low-
er than TRC-nanosuspensions 
samples. However, between 
TRC-nanosuspensions there are 
some differences: TRC 5% sam-
ple, containing the maximum 
amount of transcutol, shows 
the smallest average crystal-
line size.
DSC thermograms of nanosus-
pension formulations (Figure 
3) show an endothermic peak 
around 50°C, due to Polox-
amer melting. Thermogram of 
bulk DSC is characterized by 
a sharp endothermic peak cen-
tred around 177.9 °C followed 
by sample decomposition (Fig-
ure 3)[17]. NS-TRC 0% and 
TRC-nanosuspensions are simi-
lar, characterized by a broad 
faint peak with Tpeak centered 
around 160-161°C for TRC-nano-
suspensions and around 152°C 
for NS-TRC 0%. In agreement 
with Van’t Hoff equation [18] 
this behavior, lower Tpeak 
and broader peak, is expected 
for a very dispersed mixture 
like those of nanosuspension. 
Slightly differences in Tpeak 
of the nanosuspensions sam-
ples can be ascribed to very 
faint differences in average 
particles size, polidisper-
sivity and different hydrogen 
bonds between DCF and Trans-
cutol/Poloxamer. In agreement 
with this result the XRDP 
pattern of TRC 5% nanosuspen-
sion shows broader DCF peaks 
compared to TRC 0.5% and TRC 
1% samples. 
In Figure 4 the FTIR spec-
tra of Poloxamer, Transcutol, 
NS-TRC 0%, TRC 5%, TRC 1% and 
TRC 0.5% nanosuspensions and 
bulk DCF samples are report-
ed. The spectrum of Polox-
amer 188, a non ionic tri-
block copolymers composed of 
a central hydrophobic chain 
of polyoxypropylene flanked 
by two hydrophilic chains of 
polyoxyethylene shows sig-
nificant absorption bands due 
to OH (3600–3400 cm−1), C-O 
(1110cm−1) and C-H sp3 (2890 
cm-1) stretching [19]. The 
transcutol spectrum is very 
similar to Poloxamer one: 
the absorption band due to OH 
(3600-3400 cm-1) is accompa-
nied by that of methyl and 
methylene stretching (2982, 
2927, 2875 cm-1). Bands due 
to CH3 and CH2 scissoring 
are also present in the re-
gion 1455-1382 cm-1. C-O 
stretching is also observed 
at 1102 cm-1 with OH bending 
at 1072cm-1.
In the bulk DCF sample the 
characteristic absorption 
bands of very strong inten-
sities, due to C=O (1691 cm–
1), COO- symmetric and asym-
metric stretching (1578 cm–1, 
1452 cm-1) and the absorption 
band at 3325 cm-1 due to N-H 
stretching, which is superim-
posed on that of the large 
OH stretching signal, were 
observed [20]. Distinct ab-
sorption bands at 1296 cm–1, 
1196 cm–1 and 1156 cm-1 due to 
C–N stretching in secondary 
amines and C-C stretching vi-
brations in the aromatic ring 
at 1506 cm–1 were also ob-
served. Further O–H stretch-
ing and out of plane bending 
vibrations were noted at 2682 
cm–1 and 937 respectively. C–
Cl stretching vibrations were 
observed at 766 cm–1 and 740 
cm–1. 
The FTIR spectra of NS-TRC 0% 
and TRC-nanosuspensions are 
very similar: all absorption 
bands ascribable both to po-
laxamer or transcutol and HD2 
are evident. This result, in 
agreement with XRDP and DSC 
analysis, suggests that dif-
ferences between these sam-
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Figure 3. DSC thermograms of a) poloxamer, b) DCF nanosuspension (without 
Transcutol), c) Trc 5%, d) Trc 1%, e) Trc 0.5% nanosuspensions samples. DSC 
thermogram of bulk DCF is reported in the onset.
Figure 2. Experimental XRD spectra of a) Yttrium-stabilized zirconia-silica 
beads (beads), b) poloxamer, c) bulk DCF, d) DCF nanosuspension (without Trans-
cutol), e) TRC 5%, f) TRC 1%, g) TRC 0.5% nanosuspensions samples.
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Figure 4. FT infrared spectra of a) poloxamer, b) transcutol, c) TRC 5%, d) TRC 
1%, e) TRC 0.5%, f) TRC 0% nanosuspensions, g) bulk DCF samples. 
ples should be traced to dif-
ferent morphology, dispersion 
degree and average crystal-
lite size.
3.2. In vitro skin penetra-
tion and permeation studies
To evaluate the influence of 
Transcutol concentration on 
dermal and transdermal deliv-
ery of DCF when nanosuspen-
sions are topically applied, 
in vitro penetration and per-
meation studies through new-
born pig skin were carried 
out in non occlusive condi-
tions using Franz diffusion 
cells. Coarse suspension and 
a commercial gel formulation 
were used as control. Figure 
5 shows the % of delivered 
DCF to and accumulated in the 
skin strata for nanosuspen-
sions prepared using differ-
ent Transcutol concentration, 
coarse suspension and commer-
cial formulation prepared us-
ing the same DCF molar con-
centration (3,1 mmol/100g), 
after an 8 h experiment. As 
previously reported (see page 
148), nanosuspension pre-
pared without Transcutol (NS-
TRC 0%) enhanced DCF skin de-
livery compared to the coarse 
suspension and commercial gel 
formulation. In particular, 
commercial gel formulation 
showed the lowest drug deliv-
ery into the newborn pig skin 
(1.38% in the stratum cor-
neum, 1.15% in the epidermis 
and 0.31% in the dermis).
Furthermore, the applica-
tion of nanosuspensions and 
coarse suspension always gave 
the higher accumulation of 
DCF in the stratum corneum. 
In particular, nanosuspen-
sions prepared without Trans-
cutol (NS-TRC 0%) produced a 
drug accumulation in the SC 
approximately 16 times high-
er than the commercial gel 
and 2 times higher than the 
corresponding coarse suspen-
sion. In addition, nanosus-
pensions were able to improve 
DCF deposition, with respect 
to coarse suspensions, in the 
epidermis (6.1%) and dermis 
(3.3%). 
As previously reported, this 
enhancement in DCF skin deliv-
ery when nanosuspensions are 
applied to the skin is corre-
lated to an increased concen-
tration gradient between for-
mulation and skin due to the 
increased saturation solubil-
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ity (Figure 6) according to 
the Freundlich–Ostwald equa-
tions, and increased disso-
lution rate of the nanocrys-
tal formulation according to 
the Kelvin and Noyes–Whitney 
equations [21]. 
Unexpectedly, as reported in 
Figure 5 the increase of TRC 
in the nanosuspension for-
mulations decreased the DCF 
skin delivery. In particu-
lar, nanosuspension prepared 
using 0,5% TRC (NS-TRC 0,5%) 
produced a drug accumulation 
in the SC similar to that of 
coarse suspension (∼12.5%), 
while, the application of NS-
TRC 1% and NS-TRC 5% reduced 
the DCF accumulation (7.8 and 
4.9 % respectively). This un-
predictable behavior can be 
explained considering the av-
erage diameter and satura-
tion solubility values meas-
ured for the nanosuspension 
formulations obtained using 
different TRC concentrations. 
Indeed, the higher average 
diameter values of NS-TRC 
formulations could decrease 
the DCF dissolution veloc-
ity with respect to NS-TRC 
0%. Moreover, although TRC is 
considered a powerful solubi-
lizing agent, the increase of 
its concentration in the na-
nosuspension formulations de-
termined the DCF solubility 
decrease (Figure 6). In par-
ticular, nanosuspension pre-
pared without Transcutol (NS-
TRC 0%) showed a solubility 
value of 83 μg/ml. This val-
ue decreased to 74, 65 and 53 
μg/ml for NS-TRC 0,5%, NS-TRC 
1% and NS-TRC 5% respective-
ly. This solubility reduction 
leads to a decreased concen-
tration gradient between for-
mulation and skin, thus de-
creasing drug accumulation in 
the SC in comparison with the 
NS-TRC 0%. 
On the contrary, application 
of NS-TRC gave DCF accumula-
tion in the epidermis very 
similar to that obtained for 
NS-TRC 0% (6.1%, 8.7%, 7.1% 
and 6.1% for NS-TRC 0%, NS-TRC 
0,5%, NS-TRC 1% and NS-TRC 5% 
respectively). Furthermore, 
the application of the nano-
suspension formulation with 
the highest TRC concentration 
(NS-TRC 5%) gave a DCF permea-
tion similar to that obtained 
for NS-TRC 0%. Probably, the 
high Transcutol concentration 
in the NS-TRC 5% formulation 
determined the swelling of 
the SC intercellular lipids 
reducing the ability of the 
outer skin strata to retain 
DCF molecules that easily ac-
cumulated in the deeper lay-
ers and permeated the skin. 
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Figure 6. Water solubility of bulk DCF, DCF-TRC-nanosuspensions (NS) and DCF-
TRC-coarse suspensions (CS) at 37 °C.
Figure 5. Cumulative amount of DCF retained into and permeated through mouse 
skin layers after 8 h application of different DCF-TRC-nanosuspensions (NS-TRC; 
DCF 3.1 mmol/100g) in comparison with DCF coarse suspension without TRC (CS-TRC 
0%; DCF 3.1 mmol/100g) and Diclofenac Sandoz® gel 1% (3.1 mmol/100g). SC, stra-
tum corneum; Ep, epidermis; D, dermis; and RC, receptor compartment. 
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ic treatment of local inflamed 
skin or muscle. In particu-
lar, nanosized formulations 
(e.g., nanocrystals in the 
range of 100-1000 nm) of an-
ti-inflammatory drugs, which 
are usually poorly soluble in 
aqueous media, can be used to 
improve their local bioavail-
ability and efficacy, minimiz-
ing side effects. Indeed, na-
nocrystals can increase drug 
bioavailability by enhancing 
its dissolution velocity and 
saturation solubility, thus, 
leading to an increased con-
centration gradient with a 
consequent improved drug pen-
etration into the skin [5,6]. 
Nanocrystals are prepared as 
a suspension (nanosuspension) 
in a liquid dispersion medi-
um, usually water, stabilized 
by a suitable surfactant 
and/or polymer. Nanosuspen-
sions can be obtained by sev-
eral technologies: milling, 
high-pressure homogenization, 
impinging jet, electro-spray-
ing, liquid-based methods 
and supercritical fluid pro-
cesses [7]. Compared to oth-
er nanosizing techniques, wet 
media milling, a typical top-
down approach, is considered 
1. Introduction
Inflammation is an essential 
protective process for pre-
serving the integrity of the 
body against physical, chem-
ical, infective, and autoim-
mune causes. However, the in-
flammatory response to such 
insults may erroneously lead 
to damaging of normal tis-
sues, due to an overproduc-
tion of reactive oxygen spe-
cies (ROS), nitric oxide (NO) 
and cytokines, such as tumor 
necrosis factor-alpha (TNF-ɑ) 
[1–3].Therapeutic treatments 
involve the care of symptoms 
by interrupting the inflamma-
tory process and, if possi-
ble, the native cause. Usual-
ly, inflammation is localized 
in a specific organ or appara-
tus, like skin, subcutaneous 
tissue, muscular or osteoar-
ticular apparatus, and it can 
often become chronic. Long-
term systemic treatments with 
steroidal or non-steroidal 
anti-inflammatory drugs can 
cause onset of several side 
effects and a low drug bio-
availability at the site of 
action [4]. Topical adminis-
tration may represent a valid 
alternative to the system-
5.Topical application of diclofenac acid 
nanosuspensions reduces skin inflammation in mice
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a simple method that avoids 
organic solvents and is easy 
to scale-up [8]. During the 
milling process, drug crys-
tals break into smaller par-
ticles thanks the energy and 
shear forces generated by 
the impaction of the milling 
pearls with the drug [9].
Nanocrystals can be delivered 
by various routes of adminis-
tration, although product de-
velopment is currently being 
mainly focused on the oral 
route [10]. Dermal use of na-
nocrystals of poorly solu-
ble actives is a recent ap-
plication. Indeed, up to 10 
years ago, the dermal deliv-
ery of nanocrystals to en-
hance the local efficacy of 
actives has been completely 
neglected, both in pharmaceu-
tical and cosmetic field [11], 
and, so far, relatively lit-
tle is published about der-
mal delivery of nanocrystals 
[12–17]. Furthermore, to the 
best of our knowledge, there 
are no in vivo studies on the 
biological activity of drugs 
used in a nanocrystalline 
form and applied to the skin. 
Given that, in the present 
study, nanocrystals of di-
clofenac (2-(2-[(2,6-dichlo-
rophenyl) amino]phenyl) ace-
tic acid) (DCF) are proposed 
as a novel approach to treat 
skin inflammation, and their 
efficacy was validated in an 
animal model. DCF is one of 
the most potent and commer-
cially successful non-steroi-
dal anti-inflammatory drugs 
(NSAIDs). Due to several draw-
backs when given orally, the 
DCF is preferably adminis-
tered topically in long-term 
treatments, such as treatment 
of local muscle inflammation, 
in spite of low skin perme-
abilityof the drug. Current-
ly available commercial topi-
cal preparations contain DCF 
in salt form, because of the 
DCF free acid very low aque-
ous solubility [18]. However, 
the lipophilicity of the DCF 
acid would allow a better pen-
etration than hydrophilic DCF 
salts. Therefore, the aim of 
this work was to produce DCF 
acid nanocrystals, which are 
expected to readily penetrate 
into the skin by virtue of 
their dissolution properties.
Characterization of DCF nano-
suspensions, prepared using 
the wet media milling tech-
nique, was carried out by dif-
ferent techniques: scanning 
electron microscopy (SEM), 
differential scanning calorim-
etry (DSC), X-ray powder dif-
fractometry, Fourier trans-
form infrared spectroscopy 
and photon correlation spec-
troscopy (PCS).
Additionally, diffusion of DCF 
through mouse skin was inves-
tigated ex vivo, and the top-
ical anti-inflammatory poten-
tial of the DCF nanosuspension 
was assessed in vivo by test-
ing their activity against 
common inflammatory endpoints: 
inhibition of chemically in-
duced oedema and leucocyte 
infiltration (reflected in my-
eloperoxidase–MPO-activity). 
TPA (12-O-tetradecanoylphor-
bol-13-acetate) is common-
ly used to induce inflammation 
in animal models [19]: it is 
known to trigger the activa-
tion of protein kinase C, the 
expression of a wide variety 
of pro-inflammatory cytokines, 
such as TNF-α, and the in-
flux of neutrophils and oth-
er innate immune cells into 
skin, which closely resemble 
processes involved in chron-
ic skin inflammation [20]. The 
therapeutic efficacy of the 
nanosuspension was compared 
with those of a DCF coarse 
suspension and a commercial 
topical preparation contain-
ing diclofenac diethylamine, 
Voltaren Emulgel®.
2. Experimental
2.1 Materials
Diclofenac sodium salt (DCF-
Na) was purchased from Gale-
no (Comeana, Italy). Voltaren 
Emulgel®, an oily emulsion in 
aqueous gel containing 1.16% 
diclofenac diethylamine cor-
responding to 1% diclofenac 
sodium, was from Novartis Far-
ma (Origgio,Varese, Italy). 
Kolliphor® P188 (Poloxamer 
188), 12-O-Tetradecanoylphor-
bol 13-acetate (TPA) and all 
other reagents were purchased 
from Sigma–Aldrich (Milan, 
Italy).
2.2. Preparation of DCF acid
Diclofenac acid crystal form 
(DCF) was obtained following 
the procedure reported in a 
previous work [21]. Briefly, 
a saturated aqueous solution 
of diclofenac sodium salt was 
acidified with diluted HCl un-
til a white precipitate of 
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DCF acid was observed. The 
precipitate was filtered out, 
washed with bidistilled water 
to remove residual HCl and 
dried at 40°C overnight.
2.3. Preparation of DCF coarse 
suspension
The DCF coarse suspension was 
prepared by dispersing DCF 
bulk powder in Poloxamer 188 
bidistilled water solution 
(0.46% w/w) using an Ultra 
Turrax T25 basic (IKA, Werke, 
Germany) for 5 min at 6500 
rpm. For the preparation, the 
same amount of drug of the 
commercial Voltaren Emulgel® 
was used (3.1 mmol/100g, CS 
DCF). Drug/surfactant ratio 
(w/w) was 2:1.
2.4. Preparation and charac-
terization of DCF nanosuspen-
sion
The DCF nanosuspension was 
prepared using the wet me-
dia milling technique. Drug 
bulk powder was dispersed in 
a Poloxamer 188 aqueous solu-
tion using an Ultra Turrax T25 
basic for 5 min at 6500 rpm 
(Table 1). This coarse sus-
pension was divided in 1.5 ml 
conical microtubes contain-
ing about 0.4 g of 0.1-0.2 
mm yttrium-stabilized zirco-
nia-silica beads (Silibeads® 
Typ ZY, Sigmund Lindner, Ger-
many).The microtubes were os-
cillated at 3000 rpm for 60 
minutes using a beads-mill-
ing cell disruptor equipment 
(Disruptor Genie®, Scientif-
ic Industries, USA). The ob-
tained nanosuspensions of 
each microtubes were gathered 
and then separated from the 
milling beads by sieving.
The DCF nanosuspension was 
prepared using the same 
amount of drug of the commer-
cial Voltaren Emulgel® (3.1 
mmol/100g, NS DCF). Drug/sur-
factant ratio (w/w) was 2:1 
(Table 1).
The average diameter and 
polydispersity index (PI; a 
measure of the size distri-
bution width) of the nanosus-
pension were determined by 
photon correlation spectros-
copy (PCS) using a Zetasiz-
er nano (Malvern Instruments, 
Worcestershire, United King-
dom). Samples were backscat-
tered by a helium–neon la-
ser (633 nm) at an angle of 
173° and a constant tempera-
ture of 25 °C. Zeta potential 
was estimated using the Ze-
tasizer nano by means of the 
M3-PALS (Phase Analysis Light 
Scattering) technique. Just 
before the analysis, the DCF 
nanosuspension was diluted 
with bidistilled water.
DCF nanocrystals were evalu-
ated using scanning electron 
microscopy (SEM) (S-4100, HI-
TACHI). The sample was fixed 
on a brass stub using car-
bon double-sided, coated with 
gold blazers SCD 004 sputter 
coater for 2 minutes and ob-
served under an excitation 
voltage of 10 kV.
2.5. Solubility studies
The solubility of DCF was 
measured for the DCF bulk 
powder, coarse suspension and 
nanosuspension. The formula-
tions (n=3) were kept under 
constant stirring for 48 h in 
a thermostated bath at 37 °C. 
At preselected time inter-
vals, samples were withdrawn 
and centrifuged. 0.2 ml of the 
clear supernatant was filtrat-
ed, diluted with methanol and 
analyzed by HPLC. DCF con-
tent was quantified at 280.4 
nm using a chromatograph Al-
liance 2690 (Waters, Milan, 
Italy), equipped with a pho-
todiode array detector and a 
computer integrating appara-
tus (Empower 3). The column 
was a SunFire C18 (3.5 μm, 
4.6 mm × 100 mm, Waters), and 
the mobile phase was a mix-
ture of 30% water and 70% ace-
tonitrile (v/v), delivered at 
a flow rate of 0.7 ml/min.A 
standard calibration curve 
was built up by using working 
standard solutions. Calibra-
tion graphs were plotted ac-
cording to the linear regres-
sion analysis, which gave a 
correlation coefficient value 
(R2) of 0.999.
2.6. Differential scanning 
calorimetry
Differential scanning calorim-
etry (DSC) was performed with 
a Perkin Elmer DSC7, under 
a pure argon flux and with a 
heating rate of 10 °C/min in 
the temperature range from 30 
to 190 °C. Each sample was ac-
curately weighed (1–2 mg) in 
an aluminum pan, crimped and 
sealed. Temperature calibra-
tion was obtained using pal-
mitic acid and indium before 
and after each measurement. 
At least three different meas-
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urements were made for each 
sample and average values of 
Tpeak (peak maximum) and Ton-
set (extrapolated onset tem-
perature) were reported.
2.7. X-ray powder diffractom-
etry
X-ray powder diffraction (XRPD) 
patterns were collected with 
a Seifert X3000 diffractome-
ter operating at 35 mA and 
40 kV using Cu Kα radiation 
and equipped with a graphite 
monochromator on the diffract-
ed beam. XRPD patterns were 
recorded in step scan mode in 
the range 3° ≤2θ≤45°,with step 
size 0.05 2θ degree, collect-
ing at least 1000 counts for 
each step. The divergence and 
receiving slits were chosen in 
order to ensure a high resolu-
tion mode for the crystalline 
phases. Attention was paid 
in the sample preparation in 
order to minimize preferred 
orientation. Average crystal-
line size was estimated by the 
Scherrer equation, where the 
integral breadth was correct-
ed for instrumental broaden-
ing. The instrumental profile 
broadening was derived from 
the fitting of XRPD data ob-
tained from standard samples.
2.8. Fourier transform infra-
red spectroscopy (FTIR)
The FTIR spectra of the sam-
ples, dispersed in KBr pel-
let, were obtained using a 
Bruker Vector 22 spectropho-
tometer within the 4000– 400 
cm−1 range.
2.9. Ex vivo and in vivo drug 
penetration and permeation 
studies in mice
Male CD-1 mice (5–6 weeks old, 
25–35 g) were obtained from 
Harlan Laboratories (S. Piet-
ro al Natisone, Udine, Italy) 
and acclimatized for 1 week 
before use, with free access 
to food and water. All ani-
mal tests have been conducted 
in accordance with the guide-
lines for care and use of ex-
perimental animals of the Eu-
ropean Communities Council 
Directive 86/609/EEC.
Mice were sacrificed and 
shaved. The skin from the 
dorsal region was excised 
and mounted on Franz diffusion 
vertical cells (effective dif-
fusion area 0.785 cm2), be-
tween donor and receptor com-
partments, with the stratum 
corneum (SC) side facing the 
donor one. The receptor was 
filled with 5.5 ml of saline 
(NaCl 0.9%, w/v), continuous-
ly stirred and thermostated 
at 37 ± 0.5 °C. 20 μl of DCF 
nanosuspension, coarse sus-
pension and Voltaren Emulgel® 
(n=6 per formulation) was ap-
plied on the skin surface 
(non-occlusive conditions). 
After 1, 2, 4, 6, 8, 23 and 24 
h, the receiving solution was 
entirely withdrawn and ana-
lyzed by HPLC for drug con-
tent. After 24 h, the skin 
specimens were gently washed, 
and the SC removed by strip-
ping with adhesive tape Tesa® 
AG (Hamburg, Germany). Ep-
idermis was separated from 
dermis with a scalpel. Tape 
strips, epidermis and dermis 
were cut, each placed in a 
flask with methanol and soni-
cated for 4 min in an ice bath 
to extract the DCF. The tapes 
and tissue suspensions were 
filtered out and assayed for 
drug content by HPLC.
2.10. Mice experimental de-
sign: oedema formation and 
myeloperoxidase determination
The back skin of CD-1 mice 
(n=4 per group), housed and 
fed as above, was shaved one 
day before the experiment, 
and those animals showing no 
hair re-growth were used. TPA 
dissolved in acetone (243 µM; 
3 μg/20 μl) was applied to 
the shaved dorsal area (ap-
proximately 2 cm2) to induce 
cutaneous inflammation (day 
1). Negative control mice re-
ceived acetone only (20 μl). 
All test samples (20 μl), DCF 
nanosuspension, coarse sus-
pension, Poloxamer and com-
mercial Voltaren Emulgel®, 
were topically smeared over 
the same dorsal area 3 h af-
ter TPA application (non-oc-
clusive conditions). The pro-
cedure was repeated (at 24-h 
intervals) on day 2 and 3. On 
day 4, mice were sacrificed by 
cervical dislocation.
The inhibitory effect of DCF 
formulations on TPA-induced 
skin inflammation was deter-
mined by two biomarkers: oede-
ma formation and MPO activi-
ty. After 72 h of treatment 
(on day 4), the treated dor-
sal skin area of each mouse 
was excised and weighed to 
assess any increase indica-
tive of oedema formation, and 
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Table 1. Average diameter, polydispersity index (PI) and Zeta potential of Di-
clofenac acid (DCF) nanosuspension after millingimmediately stored at −80 °C 
[20]. MPO assay was performed 
as previously reported [20]. 
Briefly, skin biopsies were 
homogenized and centrifuged. 
The supernatant was incubat-
ed with hydrogen peroxide 
and tetramethylbenzidine and 
then assayed for MPO activity 
spectrophotometrically at 620 
nm. The MPO activity was cal-
culated from the linear por-
tion of a standard curve.
2.11. Statistical analysis of 
data
Data analysis was carried out 
with the software package 
R, version 2.10.1. Results 
are expressed as the mean ± 
standard deviation. Multiple 
comparisons of means (Tuk-
ey test) were used to sub-
stantiate statistical differ-
ences between groups, while 
Student’s t-test was used for 
comparison between two sam-
ples. Significance was tested 
at the 0.05 level of proba-
bility (p).
3. Results and Discussion
3.1. Preparation and charac-
terization of DCF nanosuspen-
sion
In this work, DCF acid na-
nosuspension was successful-
ly prepared by the wet media 
milling technique. Compo-
sition and features of the 
freshly prepared nanosuspen-
sion are shown in Table 1. 
As can be seen, the nanosus-
pension exhibited a mean di-
ameter of 279 nm and a low 
polydispersity index (0.17), 
that indicates a fairly nar-
row size distribution [9]. 
The zeta potential value was 
highly negative, -35 mV and 
the pH of the suspension was 
4.4.
The morphological features of 
DCF nanocrystals were evalu-
ated by SEM imaging. As seen 
in Figure 1, DCF crystals 
generated by milling tech-
nique have a regular shape 
with smooth and rounded sur-
faces, a narrow particle size 
distribution and diameters 
slightly less than 300 nm, as 
determined by PCS. 
In addition to the PCS par-
ticle size measurements, the 
SEM images provided evidence 
that the prepared DCF nano-
crystal suspensions were na-
nosized and homogenous in 
size and shape.
Component  Stabilizer Properties
 
  Particle size (nm) PI
Zeta potential 
(mV)I 
pH 
DCF 
0.92%(w/w) 
Poloxamer 188 
 0.46%(w/w) 
279±7.7 0.17±0.01 -35±1.3 4.4 
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A B
Figure 1. SEM images of Diclofenac acid (DCF) nanocrystals stabilized by polox-
amer 188, (A) and (B), scale bars being 2 μm and 600 nm, respectively.
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XRPD pattern of yttrium-sta-
bilized zirconia-silica 
beads, poloxamer, bulk DCF, 
DCF nanosuspension and coarse 
suspension are reported in 
Figure 2. The diffraction pat-
tern of poloxamer is charac-
terized by a peak around 19° 
2θ and a second one, larg-
er, centred around 23° 2θ. 
XRPD of beads exhibits peaks 
due to crystalline yttrium 
and zirconium oxide mixture, 
with the strongest lines cen-
tred around 30.25 and 26.72 
2θ degree. XRPD pattern of 
bulk DCF is in agreement with 
its monoclinic C2/c crystal 
structure typical to the DCF 
HD2 polymorph form [22] and 
all peaks were indexed us-
ing these structural data. No 
peaks due to others DCF poly-
morphic phases were observed 
in XRPD patterns.
In the XRPD pattern of DCF na-
nosuspension and coarse sus-
pension, the characteristic 
peaks of poloxamer are visi-
ble (at 19 and 23 2θ degree), 
while the absence of bead 
signals confirms the effective-
ness of the preparation pro-
cess. Comparison of spectra 
of nano/coarse suspensions 
with bulk DCF allowed us to 
establish that no polymorphic 
transition of DCF took place 
during their production. Fur-
ther, the relative peak in-
tensities of DCF and polox-
amer are the same of the raw 
materials (Figure 2). 
DSC thermograms of nano and 
coarse suspensions show an 
endothermic peak around 50 
°C, due to poloxamer melting 
(Figure 3). The thermogram of 
bulk DCF is characterized by 
a sharp endothermic peak cen-
tred around 177.9 °C followed 
by sample decomposition [23]. 
Nano and coarse suspensions 
display a very similar pro-
file, characterized by a broad 
faint peak with Tpeak cen-
tered around 150-152 °C. Ac-
cording to Van’t Hoff equation 
[24], this behavior (i.e. low-
er Tpeak and broader peak), 
is expected for a very dis-
persed mixture, like a nano-
suspension. Slight differences 
in Tpeak of the suspensions 
are tentatively ascribed to 
very differences in average 
particle size, in agreement 
with XRDP results.
In Figure 4, the FTIR spectra 
of bulk DCF, poloxamer, nano 
and coarse suspensions are 
reported. In the bulk DCF, 
the characteristic absorption 
bands of very strong intensi-
ties, due to C=O (1691 cm–1), 
COO– symmetric and asymmet-
ric stretching (1578 and 1452 
cm–1, respectively) and the 
absorption band at 3325 cm–1 
due to N-H stretching, which 
is superimposed on the large 
OH stretching signal, were 
observed [25]. The spectra 
also show distinct absorption 
bands at 1296, 1196 and 1156 
cm–1, due to C–N stretching 
in secondary amines and C-C 
stretching vibrations in the 
aromatic ring at 1506 cm–1. 
Further, O–H stretching and 
out of plane bending vibra-
tions are visible at 2682 and 
937 cm–1, respectively, while 
C–Cl stretching vibrations 
can be seen at 766 and 740 
cm–1. The spectrum of polox-
amer 188 shows significant 
absorption bands due to OH 
(3600–3400 cm−1), C-O (1110 
cm−1) and C-H sp3 (2890 cm-1) 
stretching[26].
The FTIR spectra of the nano 
and coarse suspensions are 
very similar: all the absorp-
tion bands ascribable both 
to poloxamer and DCF are ev-
ident. This result, in agree-
ment with XRPD and DSC analy-
ses, suggests that differences 
between these samples should 
be traced to the different mor-
phology, dispersion degree, 
and average crystallite size.
An important investigation-
al parameter for nanosuspen-
sions is the determination of 
the saturation solubility. 
In this study the water sol-
ubility at 37 °C was evalu-
ated for the DCF bulk pow-
der, coarse suspension and 
nanosuspension.
The solubility of pure DCF 
was found to be 19.88 ± 2.63 
μg/ml, which increased in the 
coarse suspension to 35.94 ± 
4.91 μg/ml, and became even 
83.14 ± 2.1 μg/ml in the na-
nosuspension. Therefore, it 
is confirmed that when parti-
cles are nanosized, satura-
tion solubility of the drug 
increases, according to the 
Freundlich–Ostwald equations 
[27].
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Figure 3 (next page). DSC thermograms of a) poloxamer, b) bulk DCF, c) DCF na-
nosuspension and d) DCF coarse suspension
Figure 2. XRD spectra of a) Yttrium-stabilized zirconia-silica beads (beads), 
b) poloxamer, c) bulk DCF, d) DCF coarse suspension and e) DCF nanosuspension 
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Figure 4 FT infrared spectra of a) bulk DCF, b) poloxamer, c) DCF coarse sus-
pension and d) DCF nanosuspension 
3.2. Ex vivo skin penetra-
tion/permeation
The penetration ability of DCF 
in nanosuspension was evalu-
ated on intact fullthickness 
mouse skin in comparison with 
the DCF coarse suspension and 
the commercial Voltaren Em-
ulgel®. Experiments were car-
ried out using 20 μl of the 
testing samples because this 
was found to be the appro-
priate dose in the proposed 
in vivo experimental proto-
col. The amount of drug ac-
cumulated into and permeated 
the whole skin is expressed 
as the percentage of the drug 
applied onto the skin. As re-
ported in Table 2, Voltaren 
gave the highest permeation 
of DCF (50%), 1.7- and 2 fold 
higher than coarse- and na-
no-suspension, respectively. 
The flux (determined as the 
slope of the linear portion 
of the plot), was 1.7 fold 
than in coarse suspension and 
1.3 fold than in nanosuspen-
sion. Moreover, it showed a 
negative lag time (calculat-
ed by extrapolating the line-
ar portion of the curve to the 
abscissa), due to the rapid 
drug exit from the skin.
By contrast, nanosuspension 
provided the highest accumu-
lation of DCF (42%; 2- and 
5.3-fold higher than that 
of coarse suspension and 
Voltaren, respectively), the 
highest value of LAC (ob-
tained as the ratio of drug 
accumulated in the skin ver-
sus drug delivered through 
the skin), 1.8- and 7-fold 
higher than course suspension 
and Voltaren, and the longest 
lag time.
More specifically, in Figure 
5, the cumulative amount of 
DCF recovered from the differ-
ent skin strata is reported 
as the mean amount of drug per 
unit of surface area (μmol/
cm2) after application of all 
the formulations tested. As 
can be seen, drug distribution 
in the different mouse skin 
strata was dissimilar. After 
application of the Voltaren 
formulation, drug deposition 
into the skin was only 0.010 
μmol/cm2 in the stratum cor-
neum, 0.179 μmol/cm2 in the 
epidermis and 0.086 μmol/cm2 
in the dermis while the high-
est amount of the drug was 
found in the receptor com-
partment (6 fold higher than 
4001200200028003600
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Figure 5 Cumulative amount of DCF retained into and permeated through mouse 
skin layers after 24 h application of DCF nanosuspension (NS DCF, 31 mol/100g) 
in comparison with DCF coarse suspension (CS DCF,3.1 mmol/100g) and Voltaren® 
(3.1 mmol/100g). SC, stratum corneum; Ep, epidermis; D, dermis; and RC, recep-
tor compartment. 
Table 2 Percentage of accumulated (in the whole skin) and permeated drug (with 
respect to the drug applied onto the skin) and total drug delivered, Local Ac-
cumulation Efficiency (LAC) values: drug accumulated into the skin/drug deliv-
ered through the skin ratio, lag time (h) and steady-state flux (J µmol/cm2/h), 
after 24 h of diffusion experiments ex vivo of DCF nanosuspension (NS DCF) in 
comparison with DCF coarse suspensions (CS DCF) and Voltaren. Values are the 
means ± standard deviation (n = 6).
the amount accumulated in the 
different skin layers). The 
application of coarse suspen-
sion gave the greatest accumu-
lation of DCF in the SC, while 
the accumulation in the der-
mis and epidermis was three 
times lower. On the contrary, 
using nanosuspension, similar 
amount of DCF were found in 
epidermis (∼0.76 µmol/cm2), 
where they reach significant-
ly higher deposition than 
Voltaren or the coarse sus-
pension. In the dermis, nano-
suspension reached deposition 
extent higher than the coarse 
suspension (0.327 μmol/cm2 vs 
0.192 μmol/cm2) and even much 
higher than Voltaren (0.327 
μmol/cm2 vs 0.086 μmol/cm2).
Ex vivo results showed that 
nanosuspension was able to 
improve DCF acid cutaneous 
deposition and, at the same 
time, to reduce its permea-
tion and flux, in comparison 
with Voltaren that provided a 
rapid and strong drug deliv-
ery to the receptor compart-
ment (mimicking the systemic 
circulation). When coarse DCF 
is transformed into nanocrys-
tals, drug saturation solu-
bility increases, namely the 
dissolved DCF acid molecules 
in equilibrium with the solid 
phase increases, consequent-
ly, increasing the concen-
tration gradient between the 
nanosuspension and the skin. 
Furthermore, the increase of 
the surface area in the na-
nosuspension also increases 
the dissolution rate: the DCF 
molecules dissolve quickly 
from the nanocrystals, which 
act as a depot in the water 
phase, and rapidly replace 
the DCF molecules penetrated 
from the water phase into the 
skin.
3.3. In vivo inflammatory re-
sponse
TPA is routinely used in skin 
inflammation protocols, since 
it triggers different sig-
nal transduction pathways and 
cellular metabolic activities 
resulting in local inflamma-
tion, migration of leucocytes 
and swelling associated with 
increased vascular permeabil-
ity [28,29].
In the short-term experiments 
presented in this paper, the 
skin of CD-1 mice was treated 
with TPA applications (once 
daily for three consecutive 
Sample Accumulated
   drug 
(% ± SD) 
Permeated 
  drug
(% ± SD)
Total drug 
delivered 
(%) 
LAC  Lag time  
(h) 
J
( mol/cm2/h±SD) 
Voltaren 8±2.0 50±2.8 58 0.2 -0.1 0.072±0.004 
CS DCF 20±5.2 24±4.5 44 0.8 2.6 0.043±0.008 
NS DCF 42±5.7 30±3.5 72 1.4 5.9 0.056±0.007 
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days) to test whether topi-
cally applied DCF nanosus-
pension inhibited the devel-
opment of acute, chemically 
induced inflammation. The more 
commonly used endpoints of 
acute inflammation are oedema, 
which is assayed by increase 
in weight, and neutrophil in-
filtration, which is measured 
by assaying for the neutro-
phil marker myeloperoxidase - 
MPO [30].
Our results, depicted in Fig-
ure 6a and b, show that the 
DCF nanosuspension partially 
suppressed TPA-induced oede-
ma, providing an oedema in-
hibition of 50%, not statis-
tically distinguishable from 
Voltaren Emulgel® (p > 0.05) 
(Figure 6a). The coarse sus-
pension had a marginal inhib-
itory effect, and Poloxamer 
produced a slightly high-
er reduction of the oedema 
(23%). Furthermore, the DCF 
nanosuspension showed a supe-
rior ability to reduce signif-
icantly MPO activity in dam-
aged tissue, than the coarse 
suspension, as shown by the 
higher inhibition value (86 
vs 67%, Figure 6b). Most im-
portantly, the nanosuspen-
sion was more effective than 
Voltaren Emulgel®, which 
achieved only 16% of MPO in-
hibition, thus, with no sta-
tistical significance compared 
to the TPA-treated skin. On 
the other hand, it was found 
that Poloxamer approached 29% 
MPO inhibition. Poloxamer is 
a nonionic block copolymer 
chemical surfactant known to 
have cytoprotective, anti-in-
flammatory activities, com-
bined with minimal toxicity, 
due to its adherence to hydro-
phobic surfaces exposed after 
cell damage, restoring normal 
hydrated surfaces [31,32]. 
This can reasonably explain 
the ability of the surfactant 
to slightly modulate the in-
flammatory events triggered by 
TPA acute tissue damage.
The efficacy of the DCF na-
nosuspension was further con-
firmed by the macroscopic ob-
servation of the treated mouse 
skin. TPA-exposed mice showed 
cutaneous lesions that ap-
peared as areas of red, crust-
ed skin with thickened tex-
ture (Figure 7). The topical 
treatment with both the DCF 
coarse suspension and Polox-
amer resulted in a moderate 
attenuation of the lesions, 
and when Voltaren Emulgel® was 
applied, the flaking, cracking 
and redness were still visi-
ble. On the contrary, a re-
markable amelioration of the 
TPA injury was observed upon 
administration of the DCF na-
nosuspension, which had a 
softening effect on the skin 
showing only mild signs of 
irritation.
These results are in per-
fect agreement with ex vivo 
skin penetration/permeation 
experiments.
4. Conclusions
In this study, DCF nanosus-
pension was successfully pre-
pared and characterized. In 
vivo and ex vivo results have 
proven the superior anti-in-
flammatory efficacy of the na-
nocrystal suspension and its 
actual ability to localize 
the drug in the site of inflam-
mation, compared to a commer-
cial product (Voltaren). In 
conclusion, this study high-
lights the great potential 
of using nanocrystal suspen-
sions as an effective strategy 
to improve topical bioavaila-
bility of poorly water-solu-
ble drugs as well as a valid 
therapeutic approach.
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Figure 6. Percentage of mouse oedema and myeloperoxidase (MPO) inhibition ob-
tained after TPA treatment followed by application of a Poloxamer water solu-
tion (0.46% w/v), Voltaren and DCF course (CS DCF) and nanosuspension (NS DCF), 
compared with TPA-only treated mice (positive control). Each bar is the mean ± 
S.D. of four animals (*p<0.05, **p<0.01, compared to TPA).
Figure 7. Photographs of dorsal skin of mice sacrificed on day 4: untreated, 
treated with TPA-only to induce inflammation, treated with TPA followed by the 
administration of a Poloxamer water solution (0.46% w/v), Voltaren and DCF 
course (CS DCF) and nanosuspension (NS DCF).
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